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Abstract 
ABSTRACT 
In spite of the fact that the introduction of novel chemotherapeutic agents to 
fight cancer as well as other infectious diseases or organ transplantation practices to 
save the life have all been developed with good intentions to cure various dreadful 
diseases that were posing challenges to the well being of human subjects. However, 
nature has tried to counter balance these effective measures by posing threat in the form 
of new challenges such as emergence of newer type of diseases including opportunistic 
and resistant infections. Further conditions had been worsening by occurrence of bird 
flu, SARS and HIV infection, which are among newer emerging diseases that come 
into existence because of exploration of scientific endeavours. 
The diseases like HIV infection is said to impair immune components of individual 
thereby facilitating establishment of opportunistic infections especially of fungal origin. 
Most of the fungal pathogens which were supposed to be non-pathogenic are now 
among the infection harboring themselves in the immunosuppressed subjects. The only 
way to combat those infections is to use new chemotherapeutic agents targeted to those 
pathogens. There had been a variety of antibiotics developed against those infections 
but there applications are limited because of the toxicity, site specific delivery (in case 
of intracellular pathogens) and emergence of resistant strains. Amphotericin B and 
nystatin, representatives of polyene class of antibiotic, were found to successfully 
eliminate fungal pathogens from systemic circulation but their toxic manifestations 
limit their application. Keeping into consideration the problems associated with 
antibiotic class of drugs, it is tempting to rely more on body's own defence measures 
and take help of antibiotics just to supplement immune strategies to ensue complete 
elimination of pathogens. The activation of immune system could be made possible by 
certain chemical agents. Among various immunomodulators, tuftsin a tetrapeptide from 
IgG (289-292 residue of the Fc region) has been found to be effective against cancer as 
well as infectious diseases. 
In our study conducted, we have tried to develop tuftsin bearing nanopartlcle 
based formulations of amphotericin B against candidiasis in murine model. In vitro 
drug release properties of the prepared microsphere-drug compositions were examined 
to compare the rank order of release from the different compositions. Among all drug: 
polymer ratio examined we chose 1: 6 ratio which give sustained release. Further those 
Amp B nanoparticles in combination to tuftsin were examined for their efficacy against 
candidiasis in model animals. Free form of amphotericin B deoxycholate and Amp B 
bearing nanoparticles were also examined for comparative study. We have shown that 
tuftsin bearing Amp B nanoparticles significantly reduce the fungal burden in vital 
organs of sacrificed animals. Amp B bearing nanoparticles also reduces the fungal 
r'" • " 
burden in comparison to free form of drug but it was not significant. Further those 
results were correlated with the increased survival in tuftsin bearing amp B 
nanoparticles treated group in comparison to Free form of drug and amp B bearing 
nanoparticles. 
In another study performed we studied the in-vivo and in-vitro renal and hepatic 
toxicity of tuftsin bearing amp B nanoparticles, amp B nanoparticles, fi-ee form of drug 
and control. We showed tuftsin bearing amp B nanoparticles and amp B nanoparticles 
had the same level of renal and hepatic parameters as in case of control (without 
treatment) whereas those parameters were elevated in case of fi"ee form of drug. Hence 
newly developed tuftsin bearing Amp B nanoparticles are non-toxic and are more 
effective in comparison to free form of drug to clear infection from systemic 
circulation. 
Tuftsin bearing liposomoses were also exploited as antigen delivery vehicles for 
activation of immune responses against cytosolic antigens of C neoformans. It seems 
that liposomes act as an antigen depot by slow release or targeting of the antigen to 
lymphoid tissues or antigen presenting cells (APCs). Besides, tuftsin incorporated on 
the surface of liposomes increased the immunogenicity of antigen by directly 
interacting with neutrophils and macrophages. Immunization of mice with Tuft-lip-
Antigen results in high antibody response against given antigen as well as isotype 
switching in favour of IgG2a.' Mice vaccinated with Tuft-lip-Ag also show increased 
survival after challenge with C. neoformans infection. Further, when immunized mice 
were treated with liposomal formulations of nystatin, shows a remarkable enhancement 
in survival rate of mice of the group immunized with Tuft-lip-Ag. 
The immunoadjuvant role of liposomised immunomodulators was studied 
against C. albicans. Mice were immunized with cytosolic fractions of C. albicans along 
with immunoadjuvants in the formulations like IFA-Antigen, Lip-Antigen and Tuft-lip-
Antigen. The results of the present study show that immunization of animals with Tuft-
lip-Ag was most effective in increasing antigen specific antibody titer, T cell 
proliferation and switching of IgG isotyping to IgG2a. Protection study shows that the 
highest number of mice survived in the group immunized with Tuft-lip-Ag (60%). 
When chemotherapy with liposomised nystatin was given to immunized mice, 100% 
survival was noted in the animals vaccinated with Tuft-lip-Ag. 
Vaccine potential of Tuft-lip-Ag was also assessed in persistently leukopenic 
mice. The animals were made leukopenic with intraperitoneal administration of 
cyclophosphamide (250 mg/kg) three days before each immunization and infection. 
The survival was found to be highest in mice immunized with Tuft-lip-Ag. However, it 
was far below in comparison to immunocompetent mice. The treatment of immunized 
mice with ensues in increased survival of the animals in dose dependent manner. Mice 
treated with Liposomised-nystatin at the dose of 3 mg/kg and 5 mg/kg show 40% and 
60% survival rates respectively. 
Keeping in view the consideration that immomunocompromised persons are 
main targets of fungal infections, we assessed the role of tuftsin in eliciting protective 
immune response against C. neoformans. The results of the present study show that 
immunization of persistently leukopenic mice with Tuft-lip-Ag was more effective in 
imparting protection as compared to other antigen-adjuvant combinations. However, 
survival rate of Tuft-lip-Ag immunized mice was far below in leukopenic mice as 
compared to that of immunocompetent mice. While immunized and non-immunized 
leukopenic mice from other groups in the study did not survive till day 50 of 
observation. When various groups of mice after immunization were treated with 
liposomal nystatin (5 mg/kg), the survival rate of leukopenic mice immunized with 
Tuft-lip-Ag increases from 30% to 60% after chemotherapy. Surprisingly, animals 
immunized with Lip-Ag and IFA-Ag followed by treatment with Lip-nystatin show 
40% and 30% survival rates respectively. Survival data is well supported by residual 
fungal burden from the vital organs of mice as fungal load was found very low in Tuft-
lip-Ag immunized mice and it was further reduced in animals which got chemotherapy 
with liposomal nystatin. From the present study it is clear that results have implications 
for the development of vaccination strategies against cryptococcosis. 
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VI I 
Review of Literature 
Nanotechnology is a rapidly expanding field today due to the multidisciplinary 
support from researchers in the academic, industry, and federal sectors. According to 
the National Nanotechnology Initiative (NNI) (NSTCCT, 2005), a multiagency US 
government program, nanotechnology is broadly defined as "The understanding and 
control of matter at dimensions of roughly 1 to 100 nanometers, where unique 
phenomena enable novel applications". The broad areas that are covered under 
nanotechnology include fiandamental nanoscale phenomena and processes, 
nanomaterials, nanoscale devices and systems, instrumentation research, meteorology, 
standards for nanotechnology, nanomanufacturing, and societal studies of benefits and 
risks of nanotechnology. 
Nanotechnology is playing an important role in providing novel therapeutics 
for the treatment of infectious diseases 'and different types of cancers. These 
nanotherapeutics have the potential to offer effective therapies with minimal side 
effects and sustained release of therapeutic agents. Targeted nanoparticles have far 
more potential to provide therapies not achievable with any other drug modalities. By 
tuning the size and surface properties of the nanoparticle, one can achieve desirable 
pharmacokinetic (PK) features suitable for its systemic administration. At present, 
95% of all new potential therapeutics has poor pharmacokinetics and 
biopharmaceutical properties (Brayden et al, 2003). Therefore, there is need to 
develop suitable drug delivery systems that distribute the therapeutically active drug 
molecule only to the site of action, with minimal access to healthy organs and tissues. 
The nanosacle drug delivery systems carry desirable attributes. They are non-toxic, 
biodegradable, stable and show slow drug release pattern. The nanoparticles can be 
tailored to provide long or short circulation times, and with careful control of size and 
surface properties, they can be directed to specific cell types within target organs. 
There are different nanoscale drug delivery systems available including liposomes, 
micelles [phospholipid-, PluronicR- (BASF Corporation, Mount Olive, NJ), poly 
(amino acid)-, and polyester-based], nanoemulsions, nanoparticulate systems (drug 
nanoparticles, polymer-, lipid-, and ceramic-based, and albumin and nanogels), and 
dendrimers for drug delivery (Table 1), but with their own limitations and 
advantages. 
Drug delivery 
systems 
Liposomes 
Phospholipid 
PiuronicR 
Poly (L-
aminoacid) 
Polyester 
Nanoemulsions 
Stage of 
developm 
ent 
Marketed 
Preclinical 
Clinical 
Preclinical 
Clinical 
Preclinical 
Preclinical 
Limitations of use 
Preparation steps have 
to be carefully 
controlled to achieve 
reproducible 
properties such as size 
and entrapment 
efficiency 
Micelles 
Limited stability in 
aqueous medium 
compared to other 
micelle types 
Some monomers have 
not been tested in 
humans 
Immune response may 
increase with diversity 
in amino acids used. 
Biodegradability of 
poly(amino acids) 
requires validation 
Polyester degrades by 
hydrolysis to produce 
acid metabolites that 
in excess may not be 
desirable 
High surfactant 
concentration of 20% 
and higher may be 
required in the 
Examples 
of application 
Amphotericin B 
Daunorubicin 
Doxorubicin 
Paclitaxel 
Camptothecin 
Diazepam 
Doxorubicin(SP 
1049C) 
Paclitaxel 
Tamoxifen 
Etoposide 
Doxorubicin 
(NK911) 
In vitro 
Antisense 
oligonucleotides 
Paclitaxel 
Doxorubicin 
Amphotericin B 
Paclitaxel 
Dexamethasone 
Benzathine 
References 
(Davidson et al, 1991) 
(Guaglianone et a\. 
1994) 
(Gabizon et al, 1989) 
(Krishnadas et al, 
2003) 
(Kooetal,2005) 
(Kristet 01,2003) 
(Danson et al, 2004) 
(Kim etal, 2004) 
(Cavallaro era/, 2004) 
(LeGarrec et al, 2004) 
(Lee et al, 2005. 
Matsumura et al. 
2004) 
(Kakizawa et al, 2001) 
(Kim et al, 2001) 
(Shuai et al, 2004. Yoo 
et al, 2004) 
(Brime et al, 2003) 
(He et a I, 2003) 
(Selii et al, 2004) 
(Santos-Magalhaes et 
formulation penicillin G al, 2000) 
Nanoparticulate systems 
Drug 
nanocrystals 
Preclinical Polylmers and 
surfactants covering 
nanocrystal surfaces 
are required to provide 
stabilization against 
aggregation 
Amphotericin B 
Etoposide, 
camptothecin, 
paclitaxel 
(Kayser et al, 2003) 
(Merisko-Liversidge et 
al, 1996) 
Polymer-based 
nanoparticles 
Preclinical Polyester degrades by 
hydrolysis to produce 
acid metabolites that 
in excess may not be 
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Tamoxifen 
Cyclosporin-A 
Theophylline 
(Shenoy eM/, 2005) 
(Molpeceres et al, 
1999) 
(Radwan^ra/, 1999) 
Lipid-based 
nanoparticles 
Preclinical En2ymatic 
degradation in vivo 
can lead to production 
of undesirable 
metabolites 
such as stearic acid 
Doxoribicin 
Camptothecin 
(Zara^/a/,2002) 
(Yang et al, 1999) 
Ceramic-based 
nanoparticles 
Albumin 
nanoparticles 
Dendrimers 
In vitro Release of 
encapsulated drugs 
may be problematic 
2-devinyl-2-(l-
hexyloxyethyl) 
pyropheophorbi 
de 
Marketed 
Preclinical 
Validation of lack of 
immune reactivity 
maybe required 
Positive charge on 
dendrimer surface may 
lead to toxicity and 
immunogenecity 
Paclitaxel 
In vitro DNA 
and antisense 
oligonucleotides 
Indometacin 
In vitro 5-
fluorouracil 
Antisense 
oligonucleotides 
(Roy et al, 2003) 
(Ibrahim et al, 2002) 
(Rhaese era/, 2003) 
(Wartlickerfl/,2004) 
(Chauhan et al, 2004) 
(Tripathi et al, 2002) 
(Hussain et al, 2004) 
Table 1 
3 
1. Biodegradable polymers as drug delivery systems 
Even though the biomedical applications of enzymatically degradable natural 
polymers such as collagen dates back thousands of years, the application of synthetic 
biodegradable polymers started only in the later half of 1960s (Barbucci et al, 2002). 
However, the past two decades saw the development of a range of new generation 
synthetic biodegradable polymers and analogous natural polymers specifically 
developed for biomedical applications. The driving force is, in part, due to the 
emergence of novel biomedical technologies including: tissue engineering, 
regenerative medicine, gene therapy, controlled drug delivery and bionanotechnology, 
all of which require biodegradable platform materials to build on. A biomaterial can 
be defined as a material intended to interface with biological systems to evaluate, 
treat, augment or replace any tissue, organ or function of the body (yS i^lliams et 
al, 1999). The essential prerequisite to qualify a substance as a biomaterial is its 
biocompatibility. Some of the important properties of a biodegradable biomaterial can 
be summarized as follows (Lloyd et al, 2002): 
1. The material should not evoke a sustained inflammatory or toxic response 
upon implantation in the body. 
2. The degradation time of the material should match with the requisite 
application. 
3. The material should have appropriate mechanical properties for the indicated 
application and the variation in mechanical properties with degradation should 
be compatible with the healing or regeneration process. 
4. The degraded products should be non-toxic, and readily get metabolized and 
cleared from the body. 
5. The material should have appropriate permeability and processibility for the 
intended application. 
6. The material should have acceptable shelf life. 
Biodegradable polymeric materials are being studied to develop therapeutic 
devices such as temporary prostheses, three-dimensional porous structures as 
scaffolds for tissue engineering and for pharmacological applications, such as drug 
delivery (both localized and targeting systems). Some of the current biomedical 
applications of biodegradable polymeric materials include: 
4 
1. Large implants, such as bone screws, bone plates and contraceptive reservoirs. 
2. Small implants, such as staples, sutures and nano- or micro-sized drug 
delivery vehicles. 
3. Plain membranes for guided tissue regeneration and 
4. Multifdament mesh or porous structures for tissue engineering (Eldridge et al, 
1999). 
2 . Hydroiyticaliy degradable polymers as biomaterials 
These biomaterials are equipped with hydroiyticaliy labile chemical bonds in 
their back-bone. The functional groups susceptible to hydrolysis include esters, ortho-
esters, anhydrides, carbonates, amides, .urethanes, ureas etc. (Pistner et al, 1993). 
They are developed by multi step (condensation) polymerization and addition (chain) 
polymerization including ring opening polymerization. In addition, several polymers 
developed by microbial bioprocess are gaining significant interest as biodegradable 
polymers. The following sections discuss some of the most promising hydroiyticaliy 
sensitive synthetic polymers developed and their biomedical applications. 
2.1. Poly (g-esters) 
Poly (a-ester)s are thermoplastic polymers with hydroiyticaliy labile aliphatic 
ester linkages in their backbone. The first synthetic suture material was successfully 
developed based on the glycolides in late 1960s. Several other aliphatic polyesters 
were developed since then as biodegradable biomaterials and are attracting significant 
attention as biomaterials due to their good biocompatibility and controllable 
degradation profiles. 
Following are the few Poly (a-ester)s, which are currently used in biomedical 
applications: 
2.1.1 Poly-glycolide 
Poly-glycolide, the first biodegradable synthetic polymer examined for 
biomedical applications, has been fabricated into a variety of forms and structures. In 
the body, poly-glycolides degrades into glycine that is excreted out or converted into 
carbon dioxide and water via the citric acid cycle (Maurus et at, 2004). However, the 
high rate of degradation, generation of acidic degraded products and low solubility 
Fig. 1 Illustration of three different structures developed from PLGA using various 
micro- and nano-fabrication techniques, (a) gas foaming (Kim et al, 2006) (b) 
microsphere sintering (Borden et al, 2002) (c) electrospinning (Katti et al, 2004). 
Another application of biodegradable PLGA is its use in guided tissue regeneration by 
providing a permeable material for space preservation. A composite PLGA-coUagen 
matrix is currently in the market (CYTOPLAST Resorbs) as a guided tissue 
regeneration membrane. 

limit the biomedical applications for poly-glycolide based biomaterials. 
2.1.2 Polv-lactides 
Lactide is a chiral molecule and exists in two optically active forms; L-lactide 
and D-lactide. The polymerization of these monomers leads to the formation of semi-
crystalline polymers. Poly (DL-lactide) (PDLLA) is an amorphous polymer with 
random distribution of L- and D-lactide units. Being a low strength polymer that can 
undergo faster degradation compared to poly(L-lactide), it is a preferred candidate for 
developing drug delivery vehicles and as low strength scaffolding material for tissue 
regeneration. It degrades into lactic acid a normal metabolic by-product, which is 
further broken down into water and carbon dioxide via the citric acid cycle (Maurus 
et al, 2004). 
2.1.3 Polv(lactide-co-glvcolide) 
Extensive research has been performed in developing a ftill range of 
poly(lactide-co-glycolide) polymers (PLGA). Both L- and DL-lactides have been used 
for co-polymerization. In the composition range of 25-75%, poly(L-lactide-co-
glycolide) forms amorphous polymers. Miller et al. have shown that the 50/50 
poly(lactide-co-glycolide) is hydrolytically very unstable and the resistance to 
hydrolytic degradation was found to be more pronounced at either end of the co-
polymer composition range (Gunatillake et al, 2006. Miller et al, 1977). The 50/50 
poly(DL-Iactide-co-glycolide) degrades in approximately 1-2 months, 75/25 in 4-5 
months and 85/15 in 5-^ months (Middleton et al, 1998.) PLGA has been shown to 
undergo bulk erosion through hydrolysis of the ester bonds and the rate of degradation 
depends on a variety of parameters including the LA/GA ratio, molecular weight, and 
the shape and structure of the matrix. These have been approved by the FDA, USA 
for use in humans. Its good processibility enables fabrication of a variety of structures 
and forms. There have been extensive investigations into its use as an ideal form for 
temporary medical applications, such as controlled drug/protein delivery systems and 
as scaffolds for tissue engineering. PLGA demonstrates good cell adhesion and 
proliferation making it a potential candidate for tissue engineering applications. 
Various studies have been performed so far using micro- and nanofabrication 
techniques to form three-dimensional scaffolds based on PLGA (Lu et al, 2004. Kim 
et al, 2006. Borden et al, 2002. Katti et al, 2002). 
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LUPRON DEPOT is a drug delivery vehicle composed of PLGA used for the 
release of a gonadotropin releasing hormone analog for prostate cancer and 
endometriosis. Several drug delivery vehicles composed of PLGA, such as 
microspheres, microcapsules, nanospheres and nanofibers have been developed for 
the controlled release of drugs or proteins. 
2.1.4 Polydioxanone 
Being polyester, polydioxanone undergoes degradation by the non-specific 
scission of the ester back bone. However, due to the high crystallinity and 
hydrophobic nature of the polymer, it can be categorized as a slow to moderately 
degrading polymer. After its administration in the body, PDS is broken down into 
glycoxylate and excreted out or converted into glycine and subsequently into carbon 
dioxide and water in a maimer similar to polyglycolides(Maurus et al, 2004). The 
polymer is known to lose its strength within 1-2 months and it's mass within 6-12 
months by hydro lytic degradation (Maurus et al, 2004). 
2.1.5 Polycaprolactone 
Polycaprolactone (PCL), semi crystalline polyester, undergoes hydrolytic 
degradation due to presence of hydrolytically labile aliphatic ester linkages; with 
relatively low rate of degradation (2-3 years). Due to the slow degradation, high 
permeability to, many drugs and non-toxicity, PCL was initially investigated as a 
long-term drug/vaccine delivery vehicle. Extensive research is ongoing to develop 
various micro- and nano-sized drug delivery vehicles based on PCL (Sinha et al, 
2004). 
2.1.6 Tri (Poiy-methylene carbonate) 
High molecular weight flexible tri(poly methylene carbonate) (PTMC) can be 
obtained by the ROP of tri-methylene carbonate. Because of its low molecular weight, 
it has been identified as a suitable material for developing drug delivery vehicles. 
Unlike the previously described polyesters, PTMC undergoes surface degradation and 
degrades much rapidly in-vivo when compared to in-vitro degradation. This is 
presumably due to the contribution of in vivo enzymatic degradation process (Zhang 
et al, 2006). 
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2.1.7 Bacterial polyesters 
Bacterial polyesters are naturally occurring biodegradable polyesters produced 
by many bacteria as their energy source. The most common polymer among this class 
is poly(3-hydroxybutyrate) (PHB), which was discovered in 1920 as produced by 
"Bacillus megatherium". In addition to a bacterial synthesis, several chemical 
synthesis routes have been developed for PHB production. The hydrolytic degradation 
of PHB results in the formation of D(-)-3-hydroxy-butyric acid which is a normal 
constituent of blood (concentrations between 0.3 and 1.3 mM). Faster degradation 
property makes it an ideal candidate for developing drug delivery vehicles that can 
achieve zero-order drug release. The in vivo degradation of these polymers is slow, 
although not many degradation studies have been performed. Attempts are currently 
underway to increase the rate of degradation of these polymers by blending them with 
more hydrophilic polymers or other low molecular weight additives to increase water 
penetration and facilitate degradation (Chen et al, 2006). 
2.2. Polyurethanes 
Based on the good biological performances of biostable polyurethanes and 
their synthetic versatility, attempts were made to use it for biodegradable vehicles. 
The unique feature of the peptide-based polymer systems is that active moieties such 
as ascorbic acid and glucose can be incorporated into the polymer which could 
potentially promote cell adhesion, viability and proliferation without any adverse 
effect (Zhang et al, 2003). These materials would require the additional property of 
having good mechanical properties and controlled degradability. This material has 
also been shown to promote favorable cell adhesion and proliferation (Bonzani et al, 
2007). 
2.3. Polv(ester amide) 
PoIy(ester amides) have good mechanical and thermal properties due to the 
hydrogen bonding ability of the amide bonds and biodegradability imparted by the 
ester bonds. The degradation of poly(ester amides) has been shovm to take place by 
the hydrolytic cleavage of the ester bonds, leaving the amide segments more or less 
intact. Attempts were also made to increase the degradation rate of poly(ester amides) 
by incorporating amino acid units in the polymer backbone. CAMEOs is a poly(ester 
amide) blend based on leucine or phenylalanine that is currently being developed for 
the site specific delivery of small hydrophobic drugs and peptides. 
2.4. Polv(ortho esters) 
Poly(ortho esters) were developed by the ALZA corporation (Alzamers) as a 
hydrophobic, surface eroding polymer designed specifically for drug delivery 
applications. Although the ortho ester linkages are hydrolytically labile, the polymer 
is hydrophobic enough such that its erosion in aqueous environments is very slow. 
The pH sensitivity of the poly (ortho esters) has lead to the development of several 
drug delivery systems using this polymer. The rate of drug release is predominantly 
controlled by the rate of polymer hydrolysis through the use of acidic or basic 
excipients. 
2.5. Polyanhydrides 
Aliphatic polyanhydrides were developed in 1932 as a fiber forming polymer 
for textile applications (Hill et al, 1932). Due to its hydrolytic instability and surface 
eroding nature, Langer et al., investigated this class of polymers as candidate 
materials for controlled drug delivery applications in 1980s (Leong et al, 1985). The 
degradation products of the polymers have been found to be non-toxic and 
biocompatible (Park et al, 1994, Leong et al, 1985, Laurencin et al, 1993a, 1993b). 
This polymer has been approved by the US FDA the controlled delivery of the 
chemotherapeutic agent BCNU for the treatment of brain cancer (Gliadels). 
2.6. Polv(anhydride-co-imide) 
Polyanhydrides are ideal candidates for drug delivery applications due to their 
surface eroding properties but have limited use because of their load bearing 
applications. The poly(anhydride-co-imides) were found to undergo degradation via 
the anhydride bonds first, followed by the hydrolysis of the imide bonds (Uhrich et 
al, 1997). 
2.7. Cross-linked polyanhydrides 
Another approach investigated to increase the mechanical strength of 
polyanhydrides is by incorporating acrylic functional groups in the monomeric units 
to form injectable crosslinkable polyanhydrides. The hydrolytic degradation products 
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of these polymers are nontoxic and composed of the corresponding diacid molecules 
and water-soluble linear methacrylic acid molecules. 
2.8. PoIv(propvIene fumarate) 
Poly(propylene fumarate (PPF) is another class of injectable biodegradable 
high-strength polymeric biomaterial developed for biomedical applications. PPF is 
known to undergo bulk erosion via hydrolysis of the ester bonds and its degradation 
time depends on several parameters, such as molecular weight, type of cross-linker, 
and cross linking density etc. The degradation products are fumaric acid, a naturally 
occurring molecule found in the tri-carboxylic acid cycle and 1,2 -propane diol, a 
common diluent of drug formulations. 
2.9. Pseudo (poly amino acid) 
Poly (amino acid) are ubiquitous, naturally-occurring biodegradable polymers. 
Their application as a biomaterial has been limited due to immunogenicity and poor 
mechanical performances. One of the most extensively examined system is the 
tyrosine derived poly(amino acids), developed with desaminotyrosyl-tyrosine alkyl 
esters as building block. These polymers have been found to be amorphous, 
hydrophobic and undergo slow hydrolytic degradation at physiological temperature. 
2.10. Polyfalkyl cvanoacrylates) 
Poly(alkyl cyanoacrylate) (PCA), a major class of biodegradable acrylate 
polymers, are used in development of nanoparticles for drug delivery application. 
Poly(alkyl cyanocrylates) are considered to be unique matrices for the delivery of 
oligodeoxynucleotides (ODN) due to the unique hydrophobic interactions the matrix 
has with ODN (Chirila et al, 2002). 
2.11. Polyphosphazenes 
In addition to organic polymers, several inorganic or inorganic-organic hybrid 
polymers have also been investigated as potential biodegradable biomaterials. Unique 
feature of polyphosphazenes, is their property to undergo both surface and bulk 
erosion making the drug release profile from these matrices significantly different 
from other polymers. The in vitro and in vivo biocompatibility of biodegradable 
polyphosphazene has been extensively investigated. (Sethuraman et al, 2006. Nair et 
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al, 2004. Nair et al, 2006. Laurencin et al, 2004. Kumbar et al, 2006). 
2.12. Polvphosphoester 
Polyphosphoesters form another interesting class of phosphorus containing 
polymers developed as biomaterials. Polyphosphoesters were developed in 1970s by 
Penczek and his colleagues (Penczek et al, 2005). Poly(lactide-co-ethyl phosphate) 
demonstrated a near zero-order release profile of chemotherapeautic drug, such as 
paclitaxel. The sustained release formulation PACLIMER based microspheres 
contains 10% (w/w) paclitaxel and has undergone Phase I human clinical trials for the 
treatment of ovarian and lung cancer. 
3. Biodegradable Microspheres As Drug Delivery System 
A key factor in the design of injectable protein /drug delivery systems is the 
choice of an appropriate biodegradable polymer. PLGA is one of the polyester 
largely used as drug delivery system because of availability of toxicological and 
chemical data, biocompatibility/histocompatibility, predictable biodegradation 
kinetics, ease of fabrication, versatility in properties, chemical integrity, commercial 
availability, variety in copolymers ratios and molecular weights, lastly and most 
important is its regulatory approval. Microsphere, composed of chemicals like 
biodegradable polymer polyvinyl alcohol (PVA) and PLGA, is one of the primary 
candidates that can be used as a carrier for sustained release of drugs and antigens 
administered either by oral or parenteral routes (Eldridge et al, 1991. O'Hagan et al, 
1993). These polymers have demonstrated excellent tissue compatibility. Moreover, 
the restorable synthetic polymers are non-toxic and have already been used for other 
biochemical applications including drug delivery (Park et al, 1994. Pistner et al, 
1993). PVA, obtained from poly(vinyl acetate) by alcoholysis, hydrolysis, or 
aminolysis (Hassan et al, 2000), is useful to deliver proteins in a controlled manner 
(Li et al, 1998). The PVA is also used to increase the loading content of water-soluble 
drug molecules into porous PLGA microcapsules (Mandal et al, 2002), as well as for 
long-term delivery of proteins (Wang et al, 1999). DL-PLGA induces only a minimal 
inflammatory response and biodegrades through the hydrolysis of its ester linkages to 
yield biocompatible lactic and glycolic acids. 
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3.1 Time of degradation 
The parameters such as co-polymer ratios, different crystalHnities, glass 
transition temperature {T) and hydrophilicity affect biodegradation profile of PLGA 
microspheres. Homogeneous degradation involves bulk erosion which is the case in 
aliphatic polyesters, erosion occurs throughout the device and rate of water 
penetration is greater than its conversion to water soluble fragments. Initially there is 
random cleavage of hydrogen bonds due to hydration followed by cleavage of 
covalent bonds. The molecular weight decreases due to continuous cleavage and 
solubilization of low molecular weight components and complete absorption. The 
carrier in such situations retains its original shape and mass until significant 
degradation has occurred (-90%). At a given time point it attains critical molecular 
weight that ultimately unsued in solubilization and mass loss. The PLA and PLGA 
chains are cleaved to monomeric acids, i.e., lactic and glycolic acids that are 
eliminated from the body through Kreb's cycle as CO2 and water. Role of enzymatic 
involvement in biodegradation is not clear. It varies depending upon other properties 
which include: molecular weight of the polymer, sequencing and cross-linking within 
the polymer backbone, surface area of the device, porosity of the matrix, 
hydrophobicity of matrix and reactive groups present. 50/50 poly(DL-lactide-co-
glycolide) degrades in approximately 1-2 months, 75/25 in 4-5 months and 85/15 in 
5-6 months (Middleton etal, 1998). 
3.2 Preparation of microspheres 
The biodegradable polymer based microspheres can be prepared by number of 
methods. Each of them has its own advantages and disadvantages. In fact the method 
of preparation plays important role on the properties of microspheres and therefore the 
desired properties should be kept in mind during the selection of a particular method 
of preparation. To formulate microspheres from the biodegradable polymer matrix, it 
is essential to select an encapsulation process, which fulfils the requirements of an 
ideal controlled release system. The attributes of the encapsulating material are 
optimal drug loading, high yield of microspheres, stability of the encapsulated drug, 
batch uniformity and inter-batch reproducibility, adjustable release profiles, low burst 
effect, free flowing microspheres. The encapsulation efficiency of the drug molecule 
should be high. The ratio of the drug molecule to the polymer should be such that the 
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largest amount of drug is encapsulated in the minimal amount of polymer. This 
reduces the mass of the material to be administered. The biological activity of the 
encapsulated drug should be maintained during the process of microsphere 
formulation. It is desirable to use a process where the exposure of the labile drug into 
strong denaturing solvent is low. The method of encapsulation should be such that by 
manipulating the formulation conditions, different types of release profiles of the 
encapsulated material can be produced. The particles should be formulated in such a 
way that minimum of the encapsulated drug is released during the burst phase. This 
will help in extending the release of the drug for a longer period of time. The 
encapsulation method used should always produce free-flowing microspheres which 
do not aggregate. As with all parenteral products, microspheres need to be sterile. 
This can be ensured by a terminal sterilization step or through aseptic processing. 
Further, in relation to safety requirements, the excipients and various solvents used in 
the processing should either be nontoxic or removed from the final product. Many 
procedures are there for the preparation of lactide-glycolide microspheres for protein 
delivery like phase separation-coacervation, double emulsion solvent technique, spray 
drying, interfacial deposition, phase inversion microencapsulation, in situ 
polymerization, and thermal cross linking, etc, but widely used techniques for 
microsphere preparation of proteins/drugs are: 
(i) Spray drying; 
(ii) Double emulsion; 
(iii) Phase separation-coacervation. 
3.2.1 Spray drying 
In principle, the biodegradable PLGA is dissolved in a volatile organic 
solvent, such as di-chloro methane, ethyl acetate or acetone, the drug in solid form is 
dispersed in polymer solution by high speed homogenization, and this dispersion is 
atomized in a stream aqueous solution of heated air. From the droplets formed, the 
solvent evaporates instantaneously yielding microspheres in typical size ranges from 
1 to 100 [im depending upon atomizing conditions. The microspheres are collected 
from air stream by a cyclone separator. Residual solvents are removed by vacuum 
drying. The process can be operated under aseptic conditions, and in closed loop 
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configurations. Spray drying in a nitrogen atmosphere is also technically feasible. 
Important advantages of this technique over other encapsulation techniques are 
proven reproducibility, well-defined control of particle size, control of drug release 
properties of resulting microspheres and process is quite tolerant to small changes of 
polymer specifications. The disadvantages include high capital investment, 
encapsulation of proteins using this technique requires lyophilisation of protein 
before dispersion and homogenization in organic polymer solution. These processing 
conditions are likely to induce aggregation and denaturation to sensitive proteins and 
antigens so stability of microencapsulated proteins during processing, release and 
storage becomes a major concern. Proteins encapsulated by this technique include 
recombinant human erythropoietin (Bittner et al, 1998), Parlodel depot 
(bromocriptine mesylate). 
3.2.2 Double emulsion method 
In this process, protein in aqueous solvent is emulsified with non-miscible 
organic solution of polymer to form a w/o emulsion. The organic solvent 
dichloromethane is mainly used, and the phase homogenization step is carried out 
using either high speed homogenizer or sonicators. This primary emulsion is then 
rapidly transferred to an excess of an aqueous medium, containing a stabilizer, 
usually polyvinyl alcohol. Again homogenization or extensive stirring is necessary to 
initially form a double emulsion of w/o/w. Subsequent removal of organic solvent by 
heat, vacuum or both results in phase • separation of polymer and core to produce 
microspheres. Instead of solvent evaporation, solvent extraction can also be 
undertaken yielding microspheres containing protein. The advantages include that the 
proteins can be used for encapsulation as an aqueous solution, scaling down is 
possible, high yields and encapsulation efficiencies are obtained. The disadvantages 
include complex process, sensitive to polymer properties, difficulties in modifying 
release profiles of drug from microspheres, arguments pertaining to shelf life of 
antigens in microspheres also apply to this process. Proteins encapsulated by this 
technique include influenza A vaccine (Hilbert et al, 1999), bovine serum albumin 
(Yang et al, 2001), lysozyme (Nam et al, 2003), recombinant human epidermal 
growth factor (Han et al, 2001), LHRH agonist (Lupron Depot) (Ogawa et al, 1998). 
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Fig. 2 Schematic diagram of OAV emulsion solvent evaporation method 
Schematic representation of a general procedure for PLGA nano/mkroparticles. 
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3.2.3 Phase separation techniques 
Protein is dispersed in solid form into solution containing dichloromethane 
and polymer. Silicon oil is added to this dispersion at a defined rate, reducing 
hormones from thermal and interfacial denaturation solubility of polymer in its 
solvent. The polymer-rich liquid phase (coacervate) encapsulates the dispersed drug 
particles and 'embryonic' microspheres subjected to hardening and washing step 
heptane. Process is quite sensitive to polymer properties, residual solvents is also an 
important issue. Proteins encapsulated by this technique diphtheria toxoid (Johansen 
ei al, 1995), Decapeptyl Depot (LHRH rated in polylactide-glycolide polymer 
matrix. Addiagonist) (Redding et al, 1984). 
3.3 Release kinetics from microspheres 
The release from the microspheres is dependent both on diffusion through the 
polymer matrix and on polymer degradation. If during, the desired release time, 
polymer degradation is considerable, then the release rate may be unpredictable and 
erratic due to breakdown of microspheres. However, the release of case, microspheres 
are covered by one or several core material from such systems is dependent 
difflisivity through the polymer barrier, solubility of core in bulk phase, size of drug 
molecule and distribution of core throughout the matrix, etc. Nature of polymer plays 
a major role in release process. Route of administration of injectable microspheres 
may also alter the duration of release. Release from PLA (poly-lactic acid) and PLGA 
(polylactic-glycolic acid) is dependent both diffusion and polymer degradation 
(Johnson et al, 1996). The possible mechanisms of drug release are: 
(i) initial release from microsphere surface; 
(ii) release through the pores dependent on spheres structure; 
(iii) diffusion through the intact polymer barrier which is dependent on intrinsic 
polymer properties and core solubility; 
(iv) diffusion through a water swollen barrier dependent on polymer 
hydrophilicity, which in turn depends on polymer molecular weight; 
(v) polymer erosion and bulk degradation, release affected by the rate of erosion 
and hydrolysis of polymer chains, leading to pore formation in matrix. 
All these mechanisms together play a part in release process. Nature of core also 
influences release kinetics either by increasing polymer degradation or by physically 
15 
binding with the polymer chain. Drug-polymer interaction leads to decreased release. 
Additives such as plasticizers decrease Tg (glass transition temperature) which leads 
to decreased diffusion rates. 
3.4 Microspheres-immune system interaction 
Microspheres are capable of forming protein depots from which protein is 
slowly released at the injection site. Interestingly, microsphere size is an important 
design parameter. Small particles, with sizes smaller than 10 ]xm can be directly taken 
up to macrophages by phagocytosis, whereas larger microspheres (greater than 10 
jam) need to undergo biodegradation before phagocytosis can occur. In this case, 
microspheres are covered by one or several layers of macrophages as a consequence 
of wound healing response to injected particles. Consequently, degradation, antigen 
release, location and antigen presentation of microspheres larger than 10 [im are to be 
different from smaller ones. Upon administration of the microspheres, a foreign-body 
response occurs, resulting in an acute initial inflammation. This initial inflammation is 
followed by the infiltration of small foreign body giant cells and neutrophils 
(Visscher et al, 1987). These immune cells could consume the released protein and 
produce an immune response. However, if protein is recognized as a self protein (e.g., 
homologous), the probability of an immune response by these cells is reduced. It is 
therefore always essential to release the protein in native conformation. The release of 
denatured protein from the microspheres may result in an unwanted immune response 
(Cleland et al, 1993). 
3.5 Applications of microspheres 
Microspheres are used in wide range of therapeutics and pharmaceutical 
applications. Various types of drugs, oligo-nucleotides, anti-tumor agents, proteins, 
peptides and vaccines have been encapsulated in these biodegradable polymers which 
are as follows: 
3.5.1 Vaccines 
3.5.1.1 Group B Streptococcus vaccine (GBS) 
Group B Streptococcus (GBS) is the leading bacterial cause of neonatal sepsis 
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Fig. 3 Intracellular compartmentalization of fluorescent PLGA microspheres 
inside peritoneal macrophages Confocal images of peritoneal macrophages 
incubated with fluorescent microspheres (green) for 1 day (A-B), 5 days (C-D), 8 
days (E-F) and 10 days (G-H). Texas Red dextran was used as late 
endossome/lysosomal marker (red). Microspheres did not co-localize with Texas Red 
dextran in the endo-lysosomal compartment at any of the analyzed time (A, C, E and 
G). (B, D, F and H): Differential interference contrast microscopy of peritoneal 
macrophages incubated with microspheres plus Texas Red dextran. Arrows show 
intracellular hydrolysis of microspheres inside macrophages. 
Ana Paula F Trombone et a\. 2007 
and meningitis. Although antibiotic prophylaxis has decreased the infection rate, the 
best long-term solution lies in the development of effective vaccines. The GBS 
capsular polysaccharide (CPS) is a major target of antibody mediated immunity. The 
feasibility of producing a GBS having the ability to produce both a local IgA immune 
response at the mucosal surface and humoral IgG response having capability of 
transplacental passive immunization was investigated (Hunter et al, 2001). 
Immunization of female mice with normal immune systems was done with these PLG 
microparticles containing GBS type III polysaccharide and CpG adjuvant 
(PLG/GBS/CpG), and results indicated a significantly higher GBS antibody response 
as compared to nonencapsulated GBS antigen or PLG encapsulated GBS PS vaccine 
without the addition of the CpG. 
3.5.1.2 Tetanus toxoid (TT) 
Tetanus is considered as a major health problem in the developing and under-
developed countries, with approximately one million new cases occurring each year. 
Tetanus is an intoxication manifested primarily by neuromuscular dysfunction. TT 
was encapsulated using PLGA with different molar compositions (50:50, 75:25) by 
w/o/w multiple emulsion technique and protein integrity was evaluated during antigen 
release in vitro in comparison to Al adsorbed TT for in vivo induction of tetanus-
specific antibodies (Jung et al, 2002). TT microspheres elicited antibody titers as high 
as conventional Al adsorbed TT which lasted for 29 weeks leading to the conclusion 
that TT microspheres can act as potential candidates for single shot vaccine delivery 
systems. 
3.5.1.3 Japanese encephalitis virus ( JEV) 
Japanese encephalitis is a disease that is spread to humans by infected 
mosquitoes in Asia. It is one of mosquito-bome viral diseases that can affect central 
nervous system and cause severe complications and even death. Vaccination is one of 
the ways of treating it. JEV vaccine was encapsulated in PLGA microspheres by 
w/o/w technique and influence of various process variables such as stirring rate, types 
and concentration of emulsifier, polymer concentration were studied on size, size 
distribution and biodegradation Rate of biodegradation of non-porous microspheres 
was slower than that of porous microspheres leading to the conclusion that PLGA 
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microspheres can be used to apply oral vaccination tlirough Payers patches across GIT 
(Khange^a/, 1996). 
3.5.1.4 Diphtheria toxoid (DT) 
Diphtheria is a communicable disease caused by Corynebacterium diphtheriae 
which colonizes and forms a pseudo membrane at the infection site. This pathogen 
produces a potent protein toxin, diphtheria toxin, which is responsible for the typical 
systemic toxemia. DT is required for active immunization against nonencapsulated 
GBS antigen or PLC encapsulated diphtheria. DT was encapsulated in different types 
of PLA and PLGA microspheres by spray drying and coacervation. Immunization of 
guinea pigs with DT microspheres made with relatively hydrophilic PLGA 50:50 
resulted in specific and sustained antibody responses to alum adjuvanted toxoid in 
contrast to microspheres made with hydrophobic polymers where very low antibody 
responses were determined confirming the feasibility of microsphere vaccines to 
induce strong, long lasting protective antibody responses after single immunization 
(Johansen et al, 1999). 
3.5.1.5 Vibrio cholerae (VO whole cell vaccine 
Cholera, an acute intestinal infection caused by the bacterium Vibrio cholerae, 
produces an enterotoxin that causes copious, painless, watery diarrhoea that can 
quickly lead to severe dehydration and death if treatment is not promptly given. For 
prevention of cholera, cholera vaccine is usually given. VC was successfully 
entrapped in the PLGA microspheres by double emulsion method with trapping 
efficiencies up to 98%. The immnunogenic potential of VC-loaded microspheres was 
evaluated in adult mice by oral immunization in comparison to VC solution. Results 
indicated that on oral administration VC-loaded microspheres physically mixed with 
amphotericin B- and VC-loaded microspheres evoke vibrio-specific serum IgG and 
IgM responses as well as vibriocidal antibody activity in mice (Yeh et al, 2002). 
3.5.2 Proteins 
3.5.2.1 Prolidase 
Deficiency of this enzyme results in chronic intractable ulcerations of the skin 
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particularly of lower limbs since it is involved in final microspheres was slower than 
that of porous micro- stages of protein catabolism. To counteract the problem, the 
enzyme was encapsulated in PLGA microspheres by w/o/w multiple emulsion 
technique in vitro and ex vivo evaluation was done and results indicated that 
microencapsulation stabilizes the enzymatic activity inside the PLGA microspheres 
controlled release system for a long-term therapy of resulting in both in vitro and ex 
vivo active enzyme release hence opening the doors for the possibility enzyme 
replacement therapy through microencapsuenlation (Genta et al, 2001). 
3.5.2.2 0-Lactoslobulin (BLG) 
Newborns prone to allergies to milk proteins which can be prevented by 
inducing oral tolerance to these proteins, based on this a major allergenic protein was 
encapsulated in PLG microspheres by w/o/w double emulsion technique. Introduction 
of tween 20 in the formulation resulted in increased encapsulation efficiency and 
better controlled protein release with reduced burst effect. Oral administration of these 
microspheres drastically reduced the amount of protein required to reduce specific 
anti-BLG IgE response, hence indicating microspheres to be optimal means of 
inducing oral tolerance (Fattal et al, 2002). 
3.5.2.3 Interferon aia (IFN a-y^ 
Interferon a2a indicated for the treatment of adults with hepatitis C virus 
infection who have compensated liver disease and have not been previously treated 
with interferon a. To improve the stability and loading efficiency of protein/drugs, a 
new microsphere delivery system comprising calcium alginate cores surrounded by 
PELA (poly DL-lactide-poIy-(ethylene glycol). Recombinant IFN (X2& as a model drug 
was entrapped within calcium alginate cores surrounded by PELA by w/o/w multiple 
techniques (Zhou et al, 2002). Core-coated microspheres stabilized the IFN a2a in 
PELA matrix. The core-coated microspheres indicated high encapsulation efficiency 
and biological retention as compared to conventional microspheres. The extent of 
burst release reduced 14% in core-coated microspheres from 31% in encapsulated in 
conventional microspheres, hence indicating a new approach for water-soluble 
macromolecular drug delivery. 
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3.5.2.4 Insulin 
Insulin is the most important regulatory hormone in the control of glucose 
homeostasis. WHO report indicated that there are more than 50 million people around 
the world who suffer diabetes and require daily parenteral injections of insulin to stay 
healthy and live normally. For the treatment of Type I diabetes still insulin is number 
one, with three subcutaneous injections to be taken per day. A controlled release 
system for a long-term therapy of this disease is the need of the hour, as this can 
obviate the need for painful injection given a number of times to the diabetes patients. 
Insulin was capsulated in blends of poly(ethylene glycol) with PLA homopolymer and 
PLG copolymer by w/o/w multiple emulsion technique with entrapment efficiencies 
up to 56 and 48% for PLG/PEG and PLA/PEG, respectively (Yeh et al, 2002). 
Insulin-loaded micro spheres were capable of controlling the release of insulin for 28 
days with in vitro delivery rates of 0.94 and 0.65 mg insulin /mg per particle per day 
in the first 4 days and steady release with rate of 0.4 and 0.43 mg insulin /mg per 
particle per day over the following 4 weeks, respectively, along with the extensive 
degradation of PLG/PEG microspheres over 4 weeks as compared to PLA/PEG 
blends which resulted in a stable particle morphology along with reduced 
fragmentation and aggregation of associated insulin. 
3.5.2.5 Lysozvnte 
Lysozyme is an enzyme that destroys bacterial cell walls by hydrolyzing the 
polysaccharide component of the cell wall. PLGA microspheres of lysozyme were 
prepared by double emulsion method and effect of urea on its release and stability was 
studied (Nam et al, 2002). Lysozyme release was enhanced from microspheres when 
urea was added into the incubation media due to suppression of protein aggregation, 
facilitated diffusion of unfolded enzyme through porous channels in microspheres and 
due to significantly reduced extent of nonspecific protein adsorption onto enlarged 
surface area of degrading polymer microspheres in presence of urea. 
3.5.3 Antibiotics 
3.5.3.1 AmpiciUin 
Successful treatment of chronic osteomyelitis requires sustained high 
concentrations of antibiotics locally within the infected bone. The efficacy of 
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biodegradable (poly-DL-lactide-co-glycolide) microspheres containing 30.7% 
ampicillin anhydrate for the local treatment of experimental staphylococcal 
osteomyelitis was evaluated in rabbits (Jacob et al, 1991). A single intramedullary 
injection of microencapsulated ampicillin (100 mg) prevented osteomyelitis in all 
seven animals tested and was as effective as a two-week course of parenteral 
ampicillin administration. In contrast, seven of ten animals treated locally with 
unencapsulated ampicillin powder developed osteomyelitis. Biodegradable antibiotic-
loaded microspheres may be of clinical benefit for the local treatment of chronic 
osteomyelitis. 
4. Liposomes 
Liposomes are vesicular structures of colloidal nature assembled when 
amphipathic lipids are dispersed in water. The vesicular structures can be thought of 
as artificial lipid bilayer membranes enclosing aqueous inner core. These were first 
described by Alec D. Bangham in 1965 (Bangham et al, 1965), and initially used as 
models for studying dynamic properties such as fluidity, phase transitions etc. of 
biomembranes. However, potential of these vesicles was soon realized as versatile 
models, reagents and tools in various scientific disciplines including, biology, 
biochemistry, and biophysics (Table 2). 
Table 2 Role of liposomes in various disciplines 
Cell biology and 
Physiology 
Biochemistry 
Biophysics 
Drug therapy and 
Enzyme therapy 
Immunology 
Excretion, cell function, trafficking and signaling, studies pertaining to 
function of genes 
Function of membrane proteins, catalysis, energy conversions etc. 
Studies of cell membranes, membrane channels, studies pertaining to 
topology of transmembrane proteins etc. 
Acts as a depot for sustained release of various anti-cancer and antifungal 
drugs as well as enzymes of therapeutic significance. 
Act as a vaccine carrier and adjuvants for increased humoral and CTL 
response. 
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Various liposome-based formulations that have been developed rely on their 
composition, colloidal, chemical, microencapsulating and surface properties. The 
applications of the liposomes range from their use as drug delivery systems 
(antimicrobial / tumor drugs etc.), vaccines, cosmetic formulations (skin care 
products, shampoos), diagnostics, ecological cleansing modules, and food 
preparations to novel breakthroughs like gene and enzyme therapy. 
4.1 COMPOSITION 
Liposomes resemble cellular biomembranes in being composed of amphiphiles 
such as phospholipids and sphingolipids, which upon their exposure to aqueous 
environment, tend to self-organize to form ordered structures. The assemblage of 
amphipathic molecules to the vesicular entities minimizes the chances of interaction 
of hydrophobic moieties with surrounding water molecules. 
A careful examination at the process of self-organization in amphiphilic 
molecules reveals that there may be three geometric factors that determine the nature 
and sizes of the vesicles viz. 
• Area of the molecule -(A) 
• Volume of their hydrocarbon chain -(V) 
• Maximum length of the chains-(L) 
The crucial combination of these parameters is geometrically the packing parameter, 
I, such that 
i = (V/A*L). 
• If the value of i is < 1/3 then spherical micelles form. 
• If 1/2 < (i) < 1 then bilayers are formed. 
In fact, the molecules that form bilayers are mainly those with large 
hydrocarbon chains, which are too bulky to fit into smaller molecular assemblies like 
micelles. A quick look at the values of (V/A*L) for different structures shows that for 
the same head-group and maximum length of the chains, molecules with double the 
volume of the hydrocarbon chain form bilayers. Thus molecules with two 
hydrocarbon chains are likely to form bilayers. The most important class of bilayer 
forming molecules is phospholipids. It becomes energetically favorable for the bilayer 
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to form closed spherical structures rather than very long planar structures. These 
closed spherical bilayers are called vesicles or liposomes. If (V/A*L) > 1 then usually 
inverted micellar structures are formed or the molecules precipitate out of the solution 
(e.g. cholesterol). Vesicles (unilamellar - single bilayer) are a Particular case from the 
family of spherically concentric multilamellar (many bilayers) structures called 
liposomes. 
The properties are also influenced by external parameters like the temperature and 
the presence of certain molecules nearby. The presence of proteins in the biological 
membranes influences their properties e.g. improves the mechanical properties. The 
best-characterized liposomes are those with lipids having packing parameter close to 
1.0. The lipid classes include phosphatidylcholine, phosphatidylserine, 
phosphatidylinositol, sphingomyelin, dicetylphosphate and DODAC. Other 
candidates are sulfatides, gangliosides, dialkylphosphates etc. Liposomes can also be 
prepared from mixture of phospholipids and the mean packing parameter is evaluated 
as weighted average of packing parameters of all the components. 
Additional constituents, apart from lipids, can also be used in preparation of 
liposomes for various reasons. For example antioxidants, chelating agents or 
cholesterol (acts as fluidity buffer) are included to enhance stability of liposomes. 
Moreover, optimization of temperature, pH and ionic strength of the medium are also 
important to produce more stable liposomes. Similarly, addition of cryoprotectants 
allows storage of liposomes in frozen arid lyophilized form, while coating with inert 
hydrophilic polymers led to increase in stability. To avoid aggregation of liposomes 
charged lipids could be incorporated. For prolonged presence of these in blood 
circulation, polyethylene glycol coated 'stealth' liposomes are used. Fusogenic 
liposomes are constituted by including glycerol, polyvinyl alcohol or reconstituted 
viral-membrane (virosomes). Actually, liposomes can be custom designed for almost 
any need by varying lipid content, additional components, size, surface charge and 
method of preparation. 
4.2 Preparation 
Several strategies are available for the preparation of various types of 
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liposomes and entrapment of various substances therein. All the procedures include 
the steps of lipid film hydration, formation of the lipid bilayer followed by removal of 
un-entrapped material. The most common method employed is sonication either by a 
probe sonicator or a bath type sonicator (Huang, 1969), others being high-pressure 
exclusion, rapid injection of an ethanolic solution of a lipid into an aqueous solution 
(Batzri and Korn, 1973) or by transgently increasing the pH of aqueous 
phospholipid dispersion (Hauser and Gains, 1982). Removal of detergents by dialysis, 
solvent infusion and reverse phase evaporation (Buboltz and Feigenson, 1999) 
results in the formation of multi-lamellar vesicles (MLVs). The simplest procedure, 
however, involves hand shaking or stirring of aqueous phospholipid dispersion. 
Following dehydration/ rehydration method, the entrapment efficiency of liposomes 
can be increased to 40% of the compound to be entrapped which is fairly higher than 
2-10% for MLVs prepared by hand shaking method. Since the size of liposome is an 
important factor in its stability and tissue distribution in vivo, exclusion through 
polycarbonate membranes is routinely used to obtain a more uniform size distribution 
in the liposome preparation. Homogenization of MLVs results in the formation of 
unilamellar vesicles. It involves some or the other form of energy to be dissipated into 
the system of lipids and aqueous solvent for preparing liposomes. 
4.3 Nomenclature based on composition 
Various constituents included in preparation of liposomes as well as other 
characteristic features can also be used as criteria for their nomenclature: 
Type Characteristic 
Conventional liposomes (CL) Neutral or negatively charged 
phospholipids with/without Cholesterol 
Fusogenic liposomes Fusogenic lipids/viral components 
pH sensitive liposomes Phosphatidyl-ethanolamine with cholesterol 
hemi succinate or PE with oleic acid liposomes 
or Cationic lipids with DOPE 
Stealth liposomes Choi and 5-10% of PEG- DSPE or GM1 
Archaeosomes Made of lipid from Archaebacteria 
Escheriosomes Composed of E. coli membrane lipid 
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Proteoliposomes Liposomes with encapsulated/surface 
attached proteins 
ImmunoHposomes Liposomes with covalentiy attached 
mono/polyclonal antibodies 
Genosomes DNA-Hposomes/lipid complexes 
Lipofectin Lipid-DNA complex 
4.4 Fate of liposomes inside host body 
Liposomes administered into host may disintegrate in bloodstream or may 
wander in the systemic circulation and picked up predominantly by macrophages. 
Actually, endothelial lining of healthy blood vessels forms an efficient barrier to the 
liposomal escape from circulation. However at the site of inflammation, endothelium 
is more permeable and allows extravasations of small liposomes. This leads to the 
rapid clearance of liposomes from the blood circulation and their capture by the 
organs of reticulo-endothelial system (Poste, 1983; Allen e/a/, 1988), corresponding 
to the tissue distribution pattern of some pathogenic microorganisms responsible for 
intracellular infections. Passive site-specific drug targeting with liposomes, as it is 
calledj may facilitate lowering of the drug dosage relative to the amount of the free 
drug used, thereby reducing the potential toxic side effects exerted by higher doses of 
the drugs. However, this clearance is too fast to benefit other tissues from it. PEG-
coated stealth liposomes have long half-life in blood circulation and may act as a 
reservoir for sustained release of the therapeutic agents for longer duration. 
Antibodies or other homing devices covalentiy attached to the surface make the 
liposome uptake tissue and cell specific. 
The applications of liposomes in drug delivery are based on physicochemical 
and colloidal characterization such as composition, size and loading efficiency and the 
stability of the carrier, as well as their biological interactions with the cells. The major 
interactions between the liposomes and cells are as follows. Lipid exchange is a long-
range interaction that involves the exchange of liposomal lipids for the lipids of 
various cell membranes. It depends on the mechanical stability of the bilayer and can 
be reduced by alloying the membrane with the cholesterol (which gives rise to greatly 
improved mechanical properties, such as increased stretching elastic modulus, 
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resulting in stronger membranes and reduced permeability). The second major 
interaction is adsorption onto cells, which occurs when the attractive forces 
(electrostatic, electrodynamic, Vander waals, hydrophobic interaction and hydrogen 
bonding etc.) exceed repulsive forces (electrostatic, steric, hydration, ondulation, 
protrusion etc.). Adsorption onto phagocytic cells is normally followed by 
endocytosis or rarely, by fusion. The fusogenic liposomes mimic the way by which 
several viruses (HIV, Sendai virus) bind and merge with cell membranes at neutral pH 
and subsequently release their content into the cytoplasm. 
4.5 Liposomes - Applications 
• Liposomes are being used for a range of therapeutic and pharmaceutical applications. 
4.5.1 Liposomes and control of multi drug resistance 
Careful selection of proper antibiotics allows successful inhibition of 
multiplication as well as complete eradication of the pathogens from the host. Each 
kind of organism may be inhibited by specific antibiotic and also by specific drug 
dose. Therefore attributes made for selection of correct antibiotics are fiindamental to 
the success of any treatment. When drug entrapped in liposomes is administered, 
liposomes act as a carrier transporting and directing antibiotics to the infected tissues 
where the drug attains fairly high concentration needed to kill the pathogens. Besides 
increasing the efficacy of the drug, liposome mediated delivery regresses chances for 
the development of resistance as the drug concentration at site of infection maintained 
throughout the treatment period. The targeted delivery also minimizes exposure of 
normal cells to the drug and thereby chances of toxic manifestation are minimal. In 
addition, this also facilitates the diffusion of the drug preferably into the infected 
locus and persistently maintains the effectiveness for a long time. 
4.5.2 Liposomes and antibacterial therapy 
Infections caused by intracellular pathogens, such as Brucella, Salmonella, 
Listeria, Legionella and Mycobacterium species, are difficult to treat with 
conventional anti-microbial chemotherapy because of the unfulfilled requirement that 
antibiotics should accumulate therapeutic levels at the intracellular site of the 
infection. When antibiotics are incorporated in liposomes, these are readily delivered 
to the endosome of macrophages, thus targeting the drug to the site of infection. 
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Liposomised streptomycin was shown to be more effective against Staphylococcus 
aureus and Escherichia coli (Fountain et al., 1985), as compared to the free drug. 
Gentamycin when encapsulated in positively charged liposomes could eliminate the 
Brucella melitensis (Harnandez-Caselles et al, 1989) and Klebsiella pneumoniae 
(Swenson et al, 1990) loads from the liver and spleen of the infected animals. 
4.5.3 Liposomes and antifungal therapy 
Systemic fungal infections occur at high frequency in the immuno-
compromised patients such as those of cancer and AIDS patients as well as patients 
with organ transplantation (Landman and Saurina, 1998; Musial et al, 1988). Drug 
of choice for the most systemic mycoses is a polyene antibiotic Amphotericin-B, that 
interacts with ergosterol in fungal cell membranes thus creating transmembrane 
channels and permitting the escape of vital ions and metabolites. This drug although 
very promising, had limited use due to its systemic toxicity. Incorporation of Amp-B 
in liposomes successfully reduces its nephrotoxicity and thus improves the therapeutic 
index (Adler-Moore and Proffitt, 2002). Numerous reports of liposomal Amp-B 
having enhanced efficacy against murine aspergillosis and candidiasis (Van Etten et 
al, 1995; Otsubo et al, 1998), and against cryptococcosis, histoplasmosis, Fusarium 
infections etc. (Graybill et al., 1982; Adier-Moore et aL, 1991; Garcia et al., 2000) 
are available. 
4.5.4 Liposomes and antiprotozoal therapy 
The first successful use of the liposomal drug delivery system in infectious 
diseases was made in the treatment of leishmaniasis. This protozoan parasite, endemic 
in many tropical and subtropical areas, enters and colonizes macrophages and thus 
can be readily targeted by liposomes. In mice, liposome encapsulated antimonies have 
been shown to be about 700-1800 tihies more effective than the free drug in 
controlling leishmaniasis (New et al., 1978). Stilbamine encapsulated in mannose 
bearing liposomes has been used in treatment of the experimental leishmaniasis. 
Interestingly, some of the anti-fimgal drugs like griseoflilvin (New et al, 1981), Amp-
B (Adler-Moore et al, 2002) and 5-fluorocytosine were demonstrated to exhibit an 
enhanced efficacy against leishmaniasis when used in the liposomal form. 
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4.5.4 Liposomes and antiviral therapy 
Liposome encapsulated macrophage stimulators, viz lymphokine, 
muramyldipeptide and its aminobuturyl analogue, were employed against Herpes 
simplex virus type-2 (HSV-2) infection (Koff e/ a/., 1983;. Ko{f et al, 1984). Murine 
Rift Valley fever virus, rhinovirus and murine hepatitis virus could be controlled 
effectively by using liposomal preparations of ribavarin, enviroxime and y-interferon 
(Szoka, 1990). Liposomal formulation of phosphonoformate, was shown to have an 
improved immunomodulation against Rausher Murine Leukemia retroviral infection 
(Szoka, 1990). Intracellular delivery of novel drugs against HIV-1, including 
antisense oligodeoxynucleotides, ribozymes and therapeutic genes, may be achieved 
by encapsulation in or association with certain types of liposomes (Duzgunes et. ai. 
1999). 
4.5.5 Liposomes and antitumor therapy 
Most of the medical applications of liposomes that have reached preclinical 
and clinical stages belong mainly to cancer ailments. It has been demonstrated that 
small-sized and long circulating liposomes can passively target different tumors 
because of extended circulation and extravasation (owing to their small size, 50-150 
nm) in tissues with enhanced vascular permeability (Gregoriadis et al, 1971; 
Gabijon and Papahadjopoulos, 1992). Long-circulating pegylated liposomes were 
able to deliver between 5 to 11 times more doxorubicin to the Kaposi's sarcoma 
lesions than to normal skin, leading to overall response rates as high as 80% 
(Northfelt et al, 1996), and also decreased uptake of drug by sensitive tissues such as 
the heart (Uziely et al, 1995). Preclinical experiments indicate that stealth liposomal 
delivery of anthracyclines is effective in decreasing the cardio toxic effect, enhancing 
antitumor activity and improving the overall therapeutic index (Alberto Gabizon, 
2000). 
4.5.6 Liposomes and Immunology 
Besides its potential application in chemotherapy and gene therapy, liposome 
technology has established itself in the area of immunology as well. The major areas 
of interest from immunological point of view are: 
• Liposomes as adjuvant 
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Liposomes may offer an alternative, versatile and universal adjuvant system 
with high safety profiles. Liposomal immunoadjuvants passively accumulate within 
regional lymph nodes and act as antigen depot by slowly releasing encapsulated 
antigenic components. Liposomes have been firmly established as immunoadjuvants 
by potentiating both antigen specific humoral (antibody production) (Alving et al, 
1995) as well as cell-mediated (cytotoxic T lymphocytes) (Owais and Gupta, 2000) 
immunity. 
" Liposomal vaccines 
Liposomal vaccines can be developed by incorporating microbes, soluble 
antigens, cytokines or deoxyribonucleic acid in liposomes. Alternatively, antigens can 
be covalently coupled to liposomal membrane for increasing their immunogenicity 
(Wassef e/ al., 1994). Also for enhanced immunopotentiation, some other agents such 
as muramyl dipeptide (MDP), lipopolysachharide, lipid A and tuftsin can also be 
incorporated into liposomes (Schroit and Fidler, 1986; Singhal et al, 1984; 
Bennett-Guerrero et al, 2000; Richards et al, 1998). 
• Liposome as immunomodulator 
Interestingly, incorporation of cytokines or other immunomodulators have 
been found to activate various immune components of the host. Activation of the 
immune system for the management of certain types of tumors like micrometastases 
and osteosarcoma is a well-accepted treatment modality. The main purpose is to 
activate macrophages and render them tumouricidal, with the specific ability to 
recognize and destroy neoplastic cells both in vitro and in vivo, while leaving normal 
cells unharmed by a non-immunological reaction mechanism that requires cell-to-cell 
contact (Tucker et al, 1981). 
5. Immunomodulators 
Normally, the Immune system of a healthy person confronts well with the 
invading pathogens leading to their successful elimination from the body. The 
establishment of the infection could be made possible in situations such as over 
exposure with the pathogens (in terms of their number as well exposure time), 
invasion with highly virulent strain or because of the suppressed immune status of the 
host. Initially, the invasion leads to local or general colonization of the infection, the 
escaping microbes once finding conducive conditions start multiplying and eventually 
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get disseminated to various parts of the body. Meanwhile immune system also gets 
activated and applies all possible measures leading to elimination of the Pathogens. 
The war keeps on going unless on overpowers other. 
Clinical management should, therefore, involve the restoration of the balanced 
immune status as the first measure to treat of various infectious diseases. Some 
bioactive substances may offer a strategy to manipulate or alter the state of the 
immune system in favor of host (Hancock and Chappie, 1999). These substances 
better referred as immunomodulators are able to influence all vital physiological 
processes and can play an important role to normalize homeostasis. Restoration of the 
balanced immune system can be achieved by using the immunomodulators that can 
support with or without other chemotherapeutic agents for their ability to eliminate 
infections. Moreover, these immunostimulatory agents or immune adjuvants are not 
only able to restore the normal response in immunocompromised conditions but can 
boost the immune status of the subjects susceptible to infective invasions due to 
environmental factors. 
Advances made in recent years regarding the understanding of molecular or 
cellular basis of immune response suggests a much bigger role of immunomodulators 
in fighting various infections. Till date- a number of immunomodulators, including 
small peptides, have been recognized that are capable of modulating the natural 
immune response either specifically or non-specifically. These immunomodulators 
can provide clinical help not only in diseases such as tuberculosis, leishmania and 
fungal Pathogens where macrophages, the prime immune cells are impaired by 
Parasites but also in common viral infections and in immunologically related neural 
disorders. Tuftsin, an established immunomodulator, for example brings 
morphological changes in the neurons of visual and sensorimotor cortices and also 
affects their locomotory activity (Chebotareva, 1990). 
The immunoregulatory therapy is a preventive therapy and if used in 
combination with chemotherapy, can help in treatment of infectious diseases as well. 
It would be even more valuable in patients who are in immunocompromised state due, 
either to infection itself or surgical trauma, irradiation, cancer chemotherapy and 
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severe burns etc (Turanek et al, 1997; Talmadge et al, 1984). In combination 
therapy, it is likely that the antibiotics/antiviral agents would reduce the magnitude of 
the infection, while the immunomodulatory agents would stimulate the natural 
immune response of the host for better fight. This eventually would help in complete 
elimination of the infection and may also reduce the chances of recurrence of 
infection. Since phagocytes are important in clearing the infectious agents, 
immunomodulators capable of stimulating their activity would be more helpful in 
such cases. 
Therapeutic use of such immunomodulators would be much precise and 
advantageous if their mode of action is understood well and is taken into account 
before using them in combination with particular vaccine/chemotherapeutic agent 
against a particular disease. 
5.1 TUFTSIN 
In 1970, Najjar and Nishioka demonstrated that leukokinnin, a leukophilic 
fraction Immunoglobulin IgG, splits under the action of specific enzyme 
(leukokininase) located in the outer membrane of neutrophils. The biological activity of 
leukokinin rests in a peptide tuftsin- so called because it was discovered at Tufts 
University (Najjar et al, 1970). Tuftsin is a 289-292 (Thr-Lys-Pro-Arg) sequence in the 
CH2 domain of the Fc fraction of the IgG molecule. 
The tetra-peptide is released physiologically as a free peptide fragment after 
enzymatic cleavage (Najjar et al, 1987). Two enzymes are responsible for the 
production of tuftsin from leukokinin, tuftsin endocarboxypeptidase, a specific 
enzyme that cleaves the heavy chain at the Arg-Glu bond between residues 292-293, 
and the membrane enzyme leucikinase acts on the bound leucokinin-S to cleave it at 
the amino end of threonine between residues 288 and 289. Tuftsin is known to bind 
specifically to macrophages, monocytes and PMN leukocytes and possess a broad 
spectrum of activities related primarily to the function of immune system (Najjar et 
al, 1987; Fridkin et al, 1989). These include potentiation of various cell ftinctions, 
such as phagocytosis, pinocytosis, motility, immunogenic response, fungicidal, 
bactericidal and tumoricidal activity (Fridkin et al, 1989). The features of tuftsin 
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coupled with its low toxicity make the tetra-peptide a promising candidate for 
immunotherapy (Nishioka et al, 1986; Khare et al, 1997). Tuftsin capacity to 
augment cellular activation is mediated by specific receptors that have been identified, 
characterized and isolated from rabbit granulocytes (Bump et al, 1986). Tuftsin and 
many of its analogs have been chemically synthesized and studied extensively for 
structure- function relationship (Nishioka etal, 1995; Gershonov etal., 1996). 
The grafting of tuftsin on microsphere would, therefore, enabled it not only in 
homing the microsphere-drug to the cells possessing receptors to recognize it but also 
stimulate these key cells of the immune system non-specifically against various 
infections (Singhal et al, 1984). Structure-ftmction studies of tuftsin indicate that its 
binding and consequent MPS activation is dependent upon rather strict conservation 
of its molecular structure. Thus the modification of the peptide at its N-terminus or 
within the chain leads to a significant reduction or even loss of biological activity and 
also its ability to bind to PMN leukocytes is reduced (Fridkin et al, 1981). 
It has been demonstrated that tuftsin could enhance non-specific defense 
against infections by activating the macrophages (Singh et al, 1992). The biological 
activity of the peptide was due to the induction of the macrophage respiratory burst 
and activated macrophages exhibited enhanced levels of NADPH oxidase, O2, H2O2 
and myeloperoxidase (MP.O). Both O2 and H2O2 damage proteins, nucleic acids and 
membranes sufficiently to kill the cell or even the whole organism. Nevertheless, for 
macrophages hypohalous acid produced by action of MPO on H2O2, has been 
identified as the major killer agent (Klebanoff e^  al, 1980). 
6. FUNGAL PATHOGENS 
Over the last several years, the frequency of life-threatening fungal infections 
has increased dramatically, particularly among cancer, diabetic and 
immunocompromised patients (Anaissie, 1992; Pfaller and Webzel, 1992; 
Richardson, 1991; Walsh, 1992). On one hand, the observed upsurge could be 
attributed to the advancement in the field of medical sciences that made possible 
improved recognition and diagnosis of fungal infections. Besides prolonged survival 
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of patients with defects in their defense mechanisms, more invasive surgical 
procedures, the use of prosthetic devices and indwelling catheters, increased 
administration of parenteral nutrition, development of resistance fungal strains to 
currently available antifungal drugs, the increase in the number of patients contracting 
AIDS and the use of peritoneal dialysis and hemodialysis are some of the potential 
opportunities offered to microbes for their establishment leading to full blown disease. 
In these patients invasive fungal infections may account for as many as 30 % of 
deaths. 
Although the occurrence of fungal drug resistance is far below in comparison 
antibacterial agents, historical precedence warns that it is only a matter of time before 
selective pressures will lead to population shifts resulting in more widespread 
resistance. Moreover, overuse and inappropriate prescription of antifungal agents has 
contributed significantly to the situation when pathogens do not respond to the 
chemotherapy. The emergence of fungi as clinically important pathogens has been 
well documented, although their role in pathogenesis of human infection has only 
recently been appreciated (Banerjee et al, 1991; Emori et al, 1993). Perhaps more 
worrisome predicament is the increased occurance of drug-resistant fungal isolates 
than their emergence as pathogens (Goff et al, 1995; Nolte et al, 1997; Nguyen et al, 
1996; Chavanet et al, 1994). 
Emergence of Candida sp. a human pathogen in national 
perspective 
Earlier Candida sp. was generally regarded as culture contaminants; however, 
in span of two decades we have witnessed the emergence of Candida as a major 
human pathogen. C. albicans is an opportunistic pathogen, which causes life-
threatening disease in immunocompromised mammalian hosts (Hurtrel et al, 1980, 
Baccarini et al, 1983). In fact, candidiasis has been found to account for ~ 52-63% of 
all nosocomial fungal infections (Nguyen et al, 1996). In 1991, Banerjee and 
colleagues reported rates of candidemia ranging from 0.28 to 0.61 cases in every 1000 
discharges in a hospital participating in the National Nosocomial Infection 
Surveillance (NNIS) system (Banerjee et al, 1991). Among NNIS system centers, 
Candida sps have been reported to be the sixth most commonly isolated pathogens 
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• Chronic mucocutaneous candidiasis - Chronic mucocutaneous candidiasis 
(CMC) is a primary immunodeficiency disease presenting with debilitating, persistent 
and refractory infections with the opportunistic yeast C. albicans (Kirkpatrick, 
1989). Infections vary from mild to lethal, are characteristically localized to the skin, 
mucous membranes and/ or nails, and as a rule do not usually progress to 
disseminated disease or sepsis (Bodey, 1993). 
• Secondary infections - Fungemia (presence of fungal pathogens in blood) is very 
common in immunosuppressed individuals. The infection is not localized to a 
particular site or organ but distributed in whole body including systemic blood 
circulation. 
Resistance to systemic or mucosal candidiasis is closely associated with a Thl type 
of response characterized by increased production of IFN-y, IL-2 and enhanced DTH, 
while susceptibility is accompanied by a Th2 type of response with increased IL-4 
and IL-6 production (Romani et al, 1992). 
7. Polyene antibiotics 
Polyene antibiotics. Amp B (Amp B), derived from fermentation products of 
Streptomyces spp remain the most effective and widely used compounds in the 
treatment of both pre-systemic and systemic fungal infections (Meyer et al, 1992). 
However, its administration is limited by dose-dependent toxicities. One such dose-
limiting toxicity is renal toxicity. Amp B induced renal toxicity is believed to be 
mediated by the drug anchoring to the cholesterol moieties within the mammalian cell 
membrane, resulting in pore formation, abnormal electrolyte flux, decrease in 
adenosine triphosphate (ATP), and eventually a loss of cell viability. Furthermore, 
these antibiotics interact with ergosterol component of fungal plasma membrane, 
causing membrane disruption, increased permeability, leakage of vital intracellular 
constituents, and eventual cell death (Bolard et al, 1986; Georgopapdakou and 
Walsh, 1996). Evidences also suggest that Amp B can cause oxidative damage, which 
may contribute to its fungicidal activity (Brajtburg et al, 1990). In general, polyene 
antibiotics have a higher affinity for the fongal sterol, ergosterol, than its mammalian 
counterpart, cholesterol, and are thus less toxic to mammalian cells (Warnock et al, 
1991). 
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7.1 Amphotericin B 
Amp B is its broad spectrum of activity and relatively low frequency of 
mycological resistance to the drug (Ellis, 2002). Despite its dose limiting toxicities, it 
has remained the 'the gold standard' for treating disseminated life threatening fungal 
infections. 
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Chemical structure of Amphotericin B 
Perhaps the main reason for lasting acceptance of Amp B deoxycholate 
(Fungizone) has a broad spectrum of activity, and today it is the best antifungal 
available against most systemic fungal infections. However, in an immunocompromised 
host. Amp B is found often ineffective. Systemic fungal infections in these patients 
have very high lethality, often between 30 % and 100 % depending upon circumstances 
(Dupont, 2002). In addition, Amp B has severe nephrotoxicity in nearly 50 % of 
patients. Consequently, use of fungizone is often compromise between efficacy and 
toxicity. Thus the effective dose is to be reduced to avoid toxicity without 
compromising the efficacy of the drug. The effectiveness of free Amp B (Fungizone®, 
Bristol-Myers Squibb, Nutley, NJ, USA; consisting of Amp B and sodium 
deoxycholate) and that of microsphere form were tested against experimentally induced 
systemic candidiasis in mice. 
There have been many attempts over the years to circumvent the problem of renal 
toxicity that forms the basis for use of other formulations of polyenes. In addition to the 
commercially available formulations of Amp B. Fungizone encapsulated in 
nanospheres, and a new cochleate formulation of Amp B is supposed to be active orally. 
Similarly Amp B-arabinogalactan conjugate is more soluble in aqueous systems. Amp 
B can be heated to make it much less toxic, and there are other less toxic derivates of 
the molecules, such as the partricin A derivative. 
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7.2 Mechanism of action 
From the 1950's until the discovery of azoles, polyenes antifungals such as 
Amp B and nystatin represented the standards of therapy for fungal infections. The 
polyenes are a class of antifungal drugs that target membranes containing ergosterol. 
Amp B and is amphipathic, having both hydrophilic and hydrophobic moieties. The 
drugs are thought to intercalate into membranes, forming a channel consisting of an 
annulus of eight Amp B molecules linked hydrophobically to the membrane sterol 
through which cellular components, especially potassium ions, leak and thereby 
destroying the proton gradient within the membrane (Vanden et al, 1994). The 
specificity of the drugs for ergosterol containing membrane is thought to be due to the 
interactions of the Amp B channel with the ergosterol in the membrane. The 
specificity of the drugs for ergosterol-containing membranes may also be associated 
with phospholipid fatty acids and the ratio of sterol to phospholipids (Vanden et al, 
1994). The drug is less likely to interact with membranes containing cholesterol. It 
has been suggested that Amp B causes oxidative damage to fungal cell membranes 
(Vanden et al, 1994). However, recent evidence suggests that Amp B has antioxidant 
effect in vivo, protecting fungal cells against oxidative attack (Osaka et al, 1997). 
7.3 Nystatin 
Nystatin (Nys) is a polyene antifungal antibiotic that has been used for the 
treatment of cutaneous, vaginal, and oral fungal infections since the 1950s (Pace and 
Schantz, 1956; Stark, 1967). Topical and oral administration of nystatin is not 
associated with significant toxicities because the compound is not absorbed through 
the skin or from the gastrointestinal tract (Newcomer et al, 1955). 
if OH if OH 6, 
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Chemical structure of Nystatin 
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To overcome its limited bioavailability nystatin has been administered 
intravenously. Previous attempts to administer nystatin parenterally in the clinical 
settings resulted in sclerosing of the veins accompanied by severe convalesscence, 
chills, fever and malaise. This eventually resulted in the discontinuation of nystatin 
therapy. To circumvent the problems associated with parenteral administration of free 
nystatin, Aronex Pharmaceuticals Inc. has recently developed Nyotran,, a liposomal 
formulation of nystatin. 
7.4 Mechanism of action 
From the 1950's until the discovery of azoles, polyenes antifungals 
such as Amp B and nystatin represented the standards of therapy for fungal infections. 
The polyenes are a class of antifungal drugs that target membranes containing 
ergosterol. Both Amp B and nystatin are amphipathic, having both hydrophilic and 
hydrophobic moieties. The drugs are thought to intercalate into membranes, forming a 
channel consisting of an annulus of eight Amp B molecules linked hydrophobically to 
the membrane sterol through which cellular components, especially potassium ions, 
leak and thereby destroying the proton gradient within the membrane (Vanden et al, 
1994). The specificity of the drugs for ergosterol containing membrane is thought to 
be due to the interactions of the Amp B channel with the ergosterol in the membrane. 
The specificity of the drugs for ergosterol-containing membranes may also be 
associated with phospholipid fatty acids and the ratio of sterol to phospholipids 
(Vanden et al, 1994). The drugs are less likely to interact with membranes containing 
cholesterol. It has been suggested that Amp B causes oxidative damage to fungal cell 
membranes (Vanden et al, 1994). However, recent evidence suggests that Amp B has 
antioxidant effect in vivo, protecting fungal cells against oxidative attack (Osaka et 
al, 1997). 
8. Host defence to fungal infections 
The body's natural barriers, i.e. the skin and epithelial surfaces, form the first 
line of defence against many pathogens including mycoses. Breach in these barriers 
through bums, intravenous catheters or the destruction of epithelial surfaces, as in 
gastrointestinal surgery, poses a major risk of fungal invasion. Normally, fungal entry is 
followed by defense reactions such as phagocytosis and killing of pathogens by the 
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neutrophils and mononuclear phagocytes. However, the conditions that lead to 
reduction in numbers of phagocytes, such as cancers, or those causing neutrophil 
dysfunction, such as diabetes mellitus, increase the risk of infection. Optimal 
phagocytosis requires blood factors such as complement and chemokines that attracts 
neutrophils to sites of pathogens, which may be defective in immunocompromised 
patients. More specific immunity to particular fungi relies on presentation of fungal 
antigens to T-lymphocytes by dedicated antigen presenting cells, which activate effector 
cell pathways, resulting in long-lasting immune defenses. Both suppression of immune 
function and the risk factors for the establishment of a fungal infection are often 
combined in seriously ill patients. Immunosuppression is not only the result of diseases 
of the immune system, but is increasingly a consequence of treatment such as 
chemotherapy, which impairs immune function. Limiting this so-called 'iatrogenic' or 
'physician-induced' immunosuppression is a major challenge to modem-day 
physicians. 
9. Antifungal drug resistance 
Unlike bacteria, for which there are standard methods for determination of the 
minimum inhibitory concentrations (MICs) and established break points MIC 
guidelines to aid the interpretation of drug susceptibility studies. Accepted methods and 
interpretable guidelines have recently been proposed for antifungal agents, although 
these still remain controversial (National Committee for Clinical Standards; 1995). 
These two facts complicate the comparison of susceptibility results reported by different 
investigators. According to the proposed guidelines, susceptibility testing with Amp B 
yields a narrow spread of MIC results, generally in the range of 0.25-l)j,g/ml. As the 
majority of fungal MICs against Amp B are < I)ag/ml (Rex et al 1995). However, 
clinical trials have demonstrated only a marginal correlation between MIC and its 
clinical outcome of Amp B. 
9.1. Intrinsic resistance 
Two types of resistance are generally referred to: intrinsic (or native or primary) 
and acquired resistance. Different Candida species have varying levels of 
susceptibility to antifungal agents. Consequently, an agent used to eradicate a 
susceptible target fungus may create a niche in the host flora, allowing an organism 
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less susceptible to an antifungal agent to survive and replicate. With the frequent and 
indiscriminate use of antifungal agents, it would presumably lead to yet another 
microbial shift induced by antimicrobial selective pressures of antimicrobial agents 
used. 
9.2. Acquired resistance 
Acquired resistance is worrying because its development is unpredictable 
and it can occur either rapidly or gradually over time. A given population of fungi is 
generally comprised of a collection of similar, yet heterogeneous strain from the same 
species. When an MIC is determined for a population, it represents the concentration 
that inhibits the majority of the microbes. This suggests that fractions of the 
population will be more or less susceptible to the test drug. If the population is 
repeatedly exposed to a concentration of an antifungal agent equal to the observed 
MIC, the less susceptible members of the population will be selected. This has been 
shown by many investigators studying the emergence of drug-resistant C albicans 
among HIV-infected individuals exposed to fluconazole (Chavanet et al., 1994; 
Pfaller ei al, 1997), Although the agreement regarding the origin of drug-resistant 
fungi has not been established, it is likely that resistance occurs as the result of several 
processes, including the emergence of several variants from the common genotype 
(Le Guennec et al, 1995; Millon et al, 1994) selection of a resistant strain from the 
mixed population (Le Guennec et al., 1995; Pfaller et al. 1994) and or reinfection 
with a new resistant strain (Pfaller et al, 1994). 
Although clinical resistance to Amp B is rare, several investigators have 
described clinical and experimental Amp B resistance (Viscoli and Castanola 1998). 
Alternations in the P-l,3-glucan composition of cell wall of C albicans, which results 
in resistance to decreased Amp B permeability, has been reported by Notario and 
colleagues (Notario et al, 1982). This resistance is phenotypic in nature and occurred 
as a result of changes in the glucan content of the cell wall induced by environmental 
stress. It is thought that decreased ergosterol contents results in fewer binding sites for 
Amp B and thus decreases its activity. 
Several physiological alternations in fungi have been linked with azole 
40 
resistance. Reduced susceptibility of ergosterol synthesis to fluconazole resulting 
from reduced affinity for, or increased production of, cytochrome P-450-dependent 
14a-demethylase (P450DM) has been reported by several investigators (Wheat et al, 
1997; Veden et al, 1992). Modification of the enzyme systems involved in sterol 
synthesis resulting in the alteration in the percentage composition of various sterol 
components in the fungal membrane has also been described. However, the most 
widely studied mechanisms of azole resistance involve a reduction in the intracellular 
accumulation of these agents despite the presence of fully susceptible P450DM within 
the cell. Decreased intracellular azole concentrations also occur as a result of 
expression of multidrug efflux pumps. This mechanism of azole resistance appears to 
be prevalent among Candida spp. Two genes (BEN"^  and CDRl) encoding proteins 
likely to be associated with energy-dependent drug efflux have been identified (White 
et al, 1998). Over expression of proteins encoded by these genes appears to result in 
an increased efflux of several unrelated agents from various fungal pathogens. 
9.3 Polyene resistance 
Despite more than 30 years of clinical use, resistance to polyenes, such as 
Amp B and nystatin is of rare occurrence. On the other hand emergence of resistant 
isolates is more worrying as these drugs are the most effective antifungals till date. 
These naturally resistant strains produce modified sterols that bind these drugs with 
lower affinity. The greater the polyene-sterol affinity, the greater the rate of flingal 
membrane damages. Hamilton-Miller proposed a "biochemical" hypothesis that 
resistance arises due to changes, either quantitative or qualitative, in the sterol content 
of the cells (Hamilton-Miller; 1973). Thus, resistant cells with altered sterol content 
should bind smaller amounts of polyenes than do susceptible cells. This decreased 
binding of polyenes in C. albicans mutants could be attributed to (i) a decrease in total 
sterol content of the cell, without concomitant changes in sterol composition: (ii) 
replacement of some or all of the polyenes-binding sterols by ones which bind 
polyenes with less efficiency, e.g., substitution of ergosterol, cholesterol, or 
stigmasterol by a 3-hydroxy or 3-oxosterol or (iii) reorientation, or masking, of 
existing sterol, so that binding with polyenes is sterically or thermodynamically less 
favored. Dick et al. studied 27 polyenes resistant C. albicans isolates obtained from 
neutropenic patients and showed that these strains had a 74 to 85% decrease in their 
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ergosterol content. Most polyene-resistant clinical isolates of C. albicans have greatly 
reduced ergosterol content in their membranes (Vanden et al; 1994). Thus, decreased 
ergosterol content may lead to decreased susceptibility to polyenes. Based on analysis 
of sterol composition, several clinical isolates of C.albicans may be defective in 
ERGl or ERG2 or ERG2 (Hayenes et al, 1996; Vanden et al; 1994). 
Mechanisms by which microbial cells might develop resistance 
1. The enzyme is overproduced, so that the drug does not inhibh the biochemical 
reaction completely. 
2. The drug target is altered so that drug cannot bind to the target. An efflux expels 
pumps the drug outside the cell. 
3. The entry of the drug is prevented at the cell membrane or cell v^ all level. 
4. The ceil has a bypass pathway that compensates for the loss of function inhibition 
due to the drug activity. 
5. Some fimgal enzymes that convert an inactive drug to an active form are inhibited. 
6. The cell secretes some enzymes to the extracellular medium, which degrades the 
drug. 
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Chapter 1 
Anti-catididiasis efficacy of 
tuftsin-beadng microsphere 
Amp B formulation 
1.1 INTRODUCTION 
Earlier efforts of using Amp B formulations have been shown to improve its 
therapeutic index in treatment of both systemic aspergillosis as well as candidiasis 
(Ahmad et al, 1990; Mehta et al, 1989; Reeta et al, 1985). Fungal infections are 
restricted mainly to the immunodebilitant subjects, one can speculate that a 
formulation of Amp B with altered pharmacokinetic properties in combination with 
some immunomodulator can synergistically subdue drug resistant fungal infections 
(Heinmann et al, 1997). The tetra peptide tuftsin (Thr-Lys-Pro-Arg), a potent 
immunomodulator, resembles an integral component of IgG (aa 289-292) and is 
released physiologically as the free peptide fragment after enzymatic cleavage. 
Tuftsin has been shown to provoke monocytes/macrophages for their natural killer 
activity against microbes (Najjar et al, 1986. Owais et al, 1993). Microsphere, 
composed of chemicals like biodegradable polymer polyvinyl alcohol (PVA) and 
PLGA, is one of the primary candidates that can be used as a carrier for sustained 
release of drugs and antigens administered either by oral or parenteral routes 
(Eldridge et al, 1991; O'Hagan et al, 1993). These polymers have demonstrated 
excellent tissue compatibility. Moreover, the restorable synthetic polymers are non-
toxic and have already been used for other biochemical applications including drug 
delivery (Park et al, 1994; Pistner et al 1993). In fact, the broad range of 
physiochemical properties, degradation rates and biocompatibility of microspheres 
give them wide scope as potential therapeutic delivery system. 
In the present study, we have demonstrated the role of biodegradable tuftsin 
bearing Amp B microspheres in the clearance of Candida sps infection fi-om the 
systemic circulation in model animals. 
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Materials and Methods 
•^2.1 Chemicals 
A^ ^ the reagents used in the studv 
Company. St. Louis, USA P„,vv ""• ' ' " * ^ ' ^ * » Sign,a Che 
1,2.2 Preparation of microspheres 
1.2.2.1 Sham microspheres 
Microparticles were prepared using oiJ-in water (0/W) emulsion by solvent 
evaporation technique as previously described (Jeffery et al, 1993). Briefly, PLGA 
(190 mg) was dissolved in 5 ml DCM. The solution was emulsified with an aqueous 
phase containing 10% PVA for 5 rnin using a Silverson L4RT Homogenizer 
(Silverson Machines, East Longmeadow, MA) and the resulting w/o/w emulsion was 
stirred under ambient temperature for 18 h to allow solvent evaporation and 
microparticle formation. The microparticles were centrifuged, washed, freeze-dried 
and stored in desiccators at 25 °C till their use in respective experiments. 
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1.2.3 Determination of entrapment efficiency 
The amount of entrapped Amp B and tuftsin in microparticles was determined 
by published method (Hora et al, 1990). Briefly, quantitatively weighed freeze-dried 
microspheres (10 mg) were dissolved in 1 ml of 0.1 N sodium hydroxide solution. 
The solution was vortexed and centrifuged for 5 min at 10000 rpm at room 
temperature. The supernatant was read at 405 nm and the concentration was 
calculated from the Amp B standard prepared in 0.1 N NaOH. Amount of the Tuftsin 
incorporated in microspheres was estimated by BCA method from same supernatant 
and concentration was calculated from the standard given. The standard was plotted 
using BSA as standard protein. 
1.2.4 In vitro release kinetics of Amp B microspheres. 
In order to assess the release kinetics of Amp B from the microspheres, 
multiple samples of each microsphere lot were weighed into micro vials. To each vial, 
1.0 ml of 20 mM sterile PBS was added. The phosphate buffer also contained a small 
amount of sodium azide to avoid microbial growth. The vials were placed at room 
temperature. The supematent was separated by centrifiigation at 10,000 rpm for 10 
minutes and replaced v^th fresh sterile PBS at every 24 to 48 h thereafter. 
Concentration of Amp B was determined by taking the absorbance 
spectrophotometric method at 405 nm and the concentration was calculated from the 
standard plotted with 20 mM PBS. 
1.2.5 Animals 
Female Balb/C mice of weight 18 ± 2 g were used in the whole study. The 
animals were given a standard pellet diet (Hindustan Lever Ltd.) and water ad libitum. 
Animals were checked daily for their mortality and morbidity prior to commencement 
of the study and only healthy animals were included in the experiment. The 
techniques used for bleeding, injection as well as sacrifice of animals were strictly 
performed following mandates approved by the Animal Ethics Committee 
(Committee for the purpose of control and supervision of Experiments on Animals, 
Govt, of India). 
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Fig. 4 Standard curve of Amp B in 0.1 N NaOH 
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Fig. 5 Standard curve of BSA protein using BCA method. 
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1.2.6 Test strain 
C albicans was obtained from candidiasis patients of Jawaharlal Nehru Medical 
College, Aligarh Muslim University, Aligarh. SD Agar/broth was used for growing 
patient isolates of C albicans. The identity of clinical isolates as C. albicans was 
confirmed by standard bio-chemical and microbiological procedures, including 
carbohydrate assimilation pattern (API 20C; Analytab Products, Bio-merieux, 
France), germ tube formation in serum containing media, and color of colonies in 
chromogenic medium (CHROM agar Candida) (Lopez-RIBOT et al, 1999). 
1.2.7 Antifungal susceptibility testing 
The MICs of Amp B for C. albicans was determined by broth microdilution 
method described by National committee for clinical laboratory standards (NCCLS, 
1995). The antifungal agents were tested over the final concentration range of 0.02 to 
5^g/ml. Testing was performed in 96 well round bottom microtitre plates. Cell 
suspension of C. albicans was prepared to give a final inoculum concentration of 2 x 
10^  cells/ml. The wells containing fungal inoculum with different concentrations of 
drugs and proper controls were incubated for 48 hours. The MIC was defined, as the 
lowest concentration of drug at which there was complete inhibition of growth. The 
MIC for C. albicans was 0.125 ^g/ml. 
1.2.8 Preparation of inoculum 
The C. albicans cells for infection were grown in 5% dextrose at 37 °C for 36 
hours. The cell suspension was centrifuged at 5,000 rpm for 15 min at 4 ° C in cooling 
centrifuge followed by washing with normal saline. The number of cells was counted 
by using hemocytometer. Each animal was challenged with 7x10^ Colony Forming 
Units (CFU) of C. albicans suspended in 0.2 ml of normal saline through i.v. route. 
1.2.9 Antifungal therapy 
The efficacy of microsphere Amp B was determined against both drug 
sensitive and drug resistant C. albicans infections in mouse model. Various dosage 
regimens were tried by administering different doses of microsphere Amp B (i.v.) in 
infected Swiss albino mice. Finally, a dose of 5-mg/kg-body weight was selected for 
evaluating the efficacy of formulated Amp B. Antifungal treatment was begun 24 
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hour after infectiorv. The infected animals were treated with various microsphere 
formulations of Amp B and were divided in five different groups as follows: 
1. Saline 
2. Empty-Micro ( Sham microsphere) 
3. Free drug (5mg/kg) 
4. Micro-Amp B (5 mg/kg) 
5. Micro-Amp B-Tuft (5 mg/kg) 
1.2.10 Assessment of antifungal efficacy 
The efficacy of microsphere Amp B was assessed by monitoring the survival of 
the animals and determining the clearance of C. albicans fi^om various organs viz. 
spleen and kidney. For survival studies, mortality of the animals was observed twice 
each day during 45 days of observation. 
1.2.11 Fungalload 
Quantitative assessment of the fungal burden in various vital organs was 
performed following published procedure (Owais et al, 1993). The animals (one from 
each group) were sacrificed on day 7"^ , 14^^ and 21^ post infectiont. The vital organs 
viz. kidney and spleen were taken out aseptically. The organs were washed 
extensively with hypotonic buffer, homogenized and serially diluted with normal 
saline. The various dilution of each (200 )xl) was dispersed on SD agar plates 
containing gentamycin to avoid bacterial contamination. After incubation of 48-72 
hours at 37 °C, the colonies were counted and the fungal load was calculated by 
multiplying with the dilution factor. 
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1.3 Results 
1.3.1 Entrapment efficiency 
The microspheres were prepared using oil-in-water (0/W) emulsion solvent 
evaporation technique as previously described (Jeffery et al, 1993). To enhance the 
loading efficiency of Amp B in microspheres, different drug: polymer ratios were 
examined and their loading efficiency was determined. Among various ratios 
examined, maximum entrapment was found in the formulation with 1:14 drug: PLGA 
ratio (Table 3) and this ratio was used for development of test drug formulation. 
Drug : PLGA ratio (in mg) 
1:02 
1:06 
1:10 
1:14 
Entrapment efficiency ± SD 
21.0 ± 3.60 
77.74 ± 2.30 
77.67 ± 1.82 
79.68 ± 2.59 
Table 3 
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1.3.2 In vitro release kinetics of Amp B loaded microspheres 
Microsphere formulations of different drug: Polymer ratios were evaluated for 
release at room temperature in 20 mM sterile PBS. As seen in Fig 7, the microsphere 
formulation with 1:2 ratio showed very rapid release. Its 50 % contents were released 
in 7 days, whereas other formulations with drug: polymer ratios 1:6 and 1:10 showed 
only 15 and 14 % release respectively. The formulation with 1:14 drug: polymer ratio 
showed much sustained release; only 9 % was released in 7 days period. From these 
results we chose formulation with 1:6 drug: polymer ratio for further in vivo 
experiments, as its entrapment was found to be sufficiently high at 77.73 % while 
showing favorable release profile. 
1.3.3 Effect of tuftsin on clearance of pathogen in animals challenged with C. 
albicans. 
The efficacy of Amp B microsphere was evaluated against experimental 
murine candidiasis. The animals were challenged with C. albicans and subsequently 
treated with various formulations of Amp B (5 mg/kg). The animals treated with 
microsphere Tuft-Amp B showed most significant decrease in fungal load in kidney 
and spleen of sacrificed animals followed by Micro Amp B (5 mg/kg), as compared to 
fi-ee drug treatment as shown in Fig. 8 and 9. As shown in the figure on day 21*' post 
infection there was negligible fungal load in animals treated with Micro Tuft Amp B. 
No animal survived in control and sham microsphere infected groups 6th day post 
infection. 
1.3.4 Increased Survival of animals infected with C. albicans after treatment with 
tuftsin bearing microsphere formulation of Amp B. 
For survival studies animals were challenged with 1X10^ cells/ animal. As seen in 
Fig. 10, no animal survived in control and sham group on day post infection. Animals 
treated with microsphere tuftsin Amp B showed maximum survival rate (80% beyond 
40 days post infection). Whereas microsphere Amp B could maintain survival rate 
only to 70 % beyond 40 days post infection and fi-ee drug showed only 40% survival. 
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Fig. 7 In vitro release kinetics of Amp B loaded microspheres at room 
temperature. Microspheres were formulated by taking different drug: polymer ratio 
and the release kinetics were perforrried as described in material and methods. 
Different drug: polymer ratio examined were 1:2, 1:6, 1:10 and 1: 14. 
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Fig. 8 EffeeTof treatment with Amp B formulations on course of C. albicans 
infection in Swiss albino mfte. Antifungal efficacy of microsphere Amp B 
formulation, in terms of residual fungal load in kidney of C. albicans infected mice. 
No animal survived in untreated control group (Group 1). The animals treated with 
sham microsphere (Group II) did not survive beyond 6"' day post-infection, therefore 
none was available for sacrifice. 
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Fig. 9 Effect of treatment with Amp B formulations on course of C albicans 
infection in Swiss albino mice. Antifungal efficacy of microsphere Amp B 
formulations, in terms of residual fungal load in spleen of C. albicans infected mice. 
No animal survived in untreated control group (Group 1). The animals treated with 
sham microsphere (Group II) did not survive beyond (i'^ day post-infection, therefore 
none was available for sacrifice. 
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Fig. 10 Survival of C.albicans infected mice following treatment with various 
formulations of Amp B. Animals were challenged with 1x10^ CFU of C albicans 
and subsequently treated with various Amp B formulations. Survival rate was 
determined on various days post challenge with C. albicans infection. 
1.4 Discussion 
Microsphere technology has been extensively used for the targeted delivery of 
different drug molecules. However, in recent years there has been growing interest of 
using microsphere for immunization as well. The main purpose to use this delivery 
system is, to provide release of protein/drug molecules in much sustained manner, 
which is a prerequisite of novel delivery system for increasing the efficacy of the 
entrapped drugs. Different ratios of poly(lactide-co-glycolides) have been 
commercially developed and are being investigated for a wide range of biomedical 
applications. It is poly-ester, which contains ester linkages in its backbone. PLGA has 
been shown to undergo bulk erosion through hydrolysis of the ester bonds. Poly 
lactide co glycolide with molar ratio 50:50 takes 1-2 months for complete degradation 
of polymer. 
Amp B, a polyene antibiotic, binds with cellular ergosterols in cellular lipid 
bilayer membranes, forming pores and causing leakage of cellular components of the 
pathogen. Inspite of its considerable renal and hepatocellular toxicity, it remains the 
only option left for treatment of various fimgal infections even after more than three 
decades of use. It had been shown that use of antifungal agents, particularly azoles, is 
shifting the population of fimgal pathogens towards species that are intrinsically 
resistant to range of antifungal agents (White, 1997; Reeta et al, 1985; Prasad et al, 
1995; Lopez-RIBOT et al, 1999; Gottesman et al, 1995). The recent reports 
regarding the development of the resistance against Amp B frustrate the clinical 
settings, and compel to find a suitable substitute, which can eliminate both drug 
sensitive as well as resistant strains of fungal pathogens (Takakazu, et al, 1999. 
Verweij et al, 1998). The potential of tuftsin bearing liposomes has already been 
established against a range of infectious agents including bacterial (Agarwal et al, 
1994) protozoan (Gupta et al, 1986) as well as fungal pathogens (Owais et al, 
1993). The present study demonstrates the potential of tuftsin bearing Amp B 
microspheres in combating the C. albicans infection in model animals. The decreased 
fungal burden in kidney and spleen of the infected animals shows the synergistic 
effect of tuftsin bearing microsphere Amp B formulation (Fig 9, 10). As an 
immunomodulator tuftsin is believed to invoke the natural killer activity of 
phagocytic cells including macrophages (Gupta et al, 1986; Heinmann et al, 1997). 
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Fig 8 and 9 clearly demonstrates that such treatment successfully obliterate 
the severity of infection as evident from reduction in initial fungal load of various 
vital organs. As well as shown in Fig 10, tuftsin bearing microsphere Amp B showed 
increased survival in comparison free drug and plain microsphere Amp B formulation 
(without tuftsin). Microsphere Amp B (without tuftsin) also showed increased 
survival when compared with free drug but it was not as potent as of tuftsin bearing 
microsphere Amp B {p value .0039). 
The success of Tuftsin bearing microsphere against candidiasis may be 
explained on the premise that antifungal activity of Amp B could be augmented in the 
presence of an immunomodulator, which have the ability to stimulate immune system 
of the host. Besides, tuftsin bearing Amp B microspheres are specifically recognized 
by macrophages and neutrophils, and may help in targeting of the drug to these cells, 
which subsequently act as the secondary depot for the drug (Najjar et al, 1986; 
Owais et al, 1993). These cells can wander to locate the site of infection (of 
chemotaxis) and help in selective targeting of the antifungal agent. Earlier, it has been 
demonstrated that prophylactic treatment with muramyl dipeptide resulted in the 
significant enhancement of antifungal activity of the Amp B (Reeta et al, 1985). 
Similar observations have been made regarding the prophylactic role of 
immunomodulator PGG glucan in enhancement of efficacy of antibiotics against 
drug-resistant bacteria (Tziananabos and Cisneros, 1996). However, in both the 
cases the enhancement of therapeutic efficacy, even in drug-resistant strains was 
achieved after prior priming the immune system with an immunomodulator. This 
suggests that stimulation of immune system play a distinct role to eliminate infection. 
Our results also provide further strength to the fact that a combination of therapeutic 
agent with an immunomodulator provides better therapeutic potential. The 
effectiveness of microspheres having Amp B and tuftsin against Candida infection 
may be attributed to combined effect of anti-fungal activity of Amp B and 
immnomodulatory potential of tuftsin. 
In summary, the new formulation of tuftsin bearing microsphere Amp B is 
highly effective in eliminating fungal infection from the host. The results offer 
opportunity to develop newer methods and combinations for the treatment of fungal 
as well as other infectious diseases. 
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Chapter 2 
In vivo and in vitro toxicity of 
tuftsin-bearing microsphere 
formulations of Amp B 
2.1 Introduction 
During the advancement in the field of chemotherapy, the most attention was 
focused on bacterial, viral and cancer infliction mainly. In contrast, fungal infections 
remained almost neglected because of the fact that neither they were very common 
nor they were posing substantial threat to the life of commoners. Of late, not only the 
incidence of opportunistic fungal infections increased to a level of threatening to the 
man. Moreover, the pathogens also started resisting to the fewer numbers of the 
antifungals available at present (Sanglard et al, 1998; Sterling and Merz, 1998; 
Wey et al, 1988). This has prompted the development of new antifungal agents and 
rediscovery or reengineering of presently available chemotherapeutic agents, which 
are in practice for treatment of infection in spite of their acute toxic manifestations 
associated with most of them. Although the discovery of new antifungal agents is 
promising, approaches to optimize efficacy and limited toxicity of currently available 
agents through rational pharmacodynamic manipulation may offer more effective 
impact (Craig, 1998; Georgeopapadakou and Walsh, 1996). 
Before introducing tuftsin bearing Amp B micropsheres in clinical setting, it is 
imperative that these formulations must undergo toxicity test as well. In the present 
study, we investigated both in vivo and in vitro toxicity of tuftsin containing 
micropshere formulations of Amp B and compared them with free form of Amp B. 
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2.2 Material and Methods 
2.2.1 Polyene antibiotics Amp B and nystatin mediated lysis of human erythrocytes. 
Human blood collected in ACD solution (Acid citrate dextrose) was 
centrifuged (1500 rpm, 15 min) and buffy coat as well as plasma was separated out. 
The red blood cells (RBCs) were washed with isotonic PBS three times by 
centrifugation. Further, the washed erythrocytes were diluted with same isotonic 
buffer and 50% hematocrit was prepared. Amp B (Free as well as microsphere forms) 
were added at the cone, of 10)ag/ml to erythrocyte suspension. The free forms of the 
drugs were dissolved in 50)^ 1 of DMSO and finally volume was made up to 1 ml with 
PBS (5% DMSO). To study haemolysis, solution of RBCs was incubated with 1 ml of 
free as well as microsphere drugs (10 |ig/ml) at 37 °C for 1 hour. After 1 hour the 
reaction mixture was centrifuged at 1500 rpm and supernatant was collected and 
analyzed for hemoglobin by UV-Visible spectroscopy at 576 nm. The percent 
haemolysis was determined by following equation: % haemolysis = 100 (Abs-Abso / 
Absioo - Abso), where Abs, Abso and Absioo are the absorbances for the sample, 
control (5% DMSO) with no Amp B and control (erythrocytes in 1% Triton X-100 ) 
in presence of 10 jxg/ml Amp B. 
2.2.2 Assessment of hepatic and renal toxicity. 
Hepatic and renal toxicities weremonitered by applying multidose regimen to 
determine biochemical profiles of serum creatinine, aspartate transaminase (AST), 
alkaline phosphatase and total bilirubin. The blood was collected from the mice of 
different groups before first and after the last dose of the drug administration. The 
blood was allowed to clot at room temperature and serum was separated for 
investigation. 
The animals were divided into groups as follows: 
1. Control 
2. Treated with Free Amp B (5 mg/kg) 
3. Treated with Micro-Amp B (5 mg/kg) 
4. Treated with Tuft-micro-Amp B (5 mg/kg) 
The treatment with various forms of Amp B was given via intraperitoneal route on 
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days 1, 4 and 7. The dose of the drug given to the infected animal was as follows: 
1. Control 
2. Free Amp B (5 mg/kg) 
3. Micro-Amp B (5 mg/kg) 
4. Tuft-micro-Amp B (5 mg/kg) 
Results 
2.3 Results 
2.3.1 Incorporation of Amp B in microspheres markedly reduces their toxicity to 
erythrocytes 
Among various formulations, free Amp B was found to show maximum 
toxicity to erythrocytes as evident from drug induced hemolytic action on 
erythrocytes. The incorporation of Amp B in conventional as well tuftsin bearing 
microspheres results in diminution of its toxic property to a surprisingly low level. 
Amp B in tuftsin containing microsphere was showing less toxicity to erythrocytes 
than that of conventional liposomal preparation of same drug (Fig. 11). 
2.3.2 Drug induced toxicity in animal models 
Treatment with tuftsin bearing microsphere formulation of Amp B and 
microsphere Amp B was found to be associated with less hepatotoxic^^^as ^vell as 
nephrotoxicity as compared to the free form of drug (Table 4). 
Table 4 Effect of Amp B on hepatic and renal function panraieters of mice y /. 
Group 
Untreated 
Free-Amp B 
Micro-Amp B 
Tuft-micro-
AmpB 
S.Bilirubin 
(mg/dl) 
0.27± 0.006 
0.92± 0.16 
0.28± 0.02 
0.28± 0.012 
AST 
(U/litre) 
43.65±3.93 
80.75±2.41 
67.74±3.07 
64.47±2.76 
S. Creatinine 
(mg/dl) 
1.95± 0.16 
2.40± 0.56 
2.08± 0.16 
1.85± 0.04 
Alkaline 
phosphatase 
(mg/dl) 
6.34±1.65 
11.31±1.23, 
7.18±1.76 
6.68±0.25 
The data is the mean ± S.D. of three independent values. 
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Discussion 
2.4 Discussion 
The results of the present investigation clearly demonstrate a major reduction 
in the toxicity of Amp B upon incorporation in the Tuftsin bearing microsphere 
compared with free Amp B. Among various antifungal agents, polyene antibiotics 
have been supposed to be highly toxic to the host cells specially erythrocytes 
(Legrand et al, 1992). To evaluate the toxicity of tuftsin containing microsphere Amp 
B, erythrocytes were incubated with various formulations of Amp B and it was 
compared with that of free Amp B. We found that Amp B incorporated in tuftsin free 
as well tuftsin loaded microsphere induced least haemolysis as compared to free Amp 
B in vitro. These results are also supported by in vivo results of toxicity of free Amp B 
in comparison to tuftsin free and tuftsin loaded Amp B formulations. The observed 
less toxicity of tuftsin bearing Amp B microsphere may allow accommodation of 
much higher doses of the drug. The reduced toxicity of the Tuftsin-microsphere-Amp 
B may in part be due to higher stability of these microspheres. 
The toxicity of the Amp B was also assessed by analysis of liver and renal 
function tests. Free Amp B, microsphere Amp B and Tuftsin microsphere Amp B at 
the dose of 5 mg/kg were injected intraperitoneally into the animals. The level of 
bilirubin was highest in Amp B (5 mg/kg) in comparison to Micro Amp B, Tuftsin-
Micro-Amp B and untreated groups. The deterioration of various vital organs 
functioning again suggests the cautious use of drugs that are meant for the treatment 
of opportunistic infection. 
Amphotericin B deoxycholate (5 mg/kg), tuftsin- micro-amp B (5 mg/kg) and 
microsphere amp B (5 mg/kg) were injected into mice intraperitoneally on days 1, 2 
and 3. The renal toxicity was assessed by estimating serum creatinine level in mice. 
We found that the level of serum creatinine was elevated in the mice treated with free 
Amp B in comparison to control (untreated), Amp B microsphere and Tuftsin Amp B 
microsphere. Amp B in free form has been found to bind with low-density 
lipoproteins (LDL) and there are high numbers of renal LDL receptors that mediate 
the cellular uptake of Amp B. This interaction of Amp B, LDL and renal receptors is 
believed to be a major contributor to the dose-limiting nephrotoxicity of Amp B. Low 
renal toxicity of Amp B microspheres is due to reduced distribution of Amp B in 
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kidneys of mice treated with tuftsin-free or tuftsin loaded Amp B microspheres. The 
preferential uptake of microsphere Amp B by hepatic and splenic macrophages leads 
to reduced availability of the drug to kidneys and other organs, which ultimately helps 
in reducing nephrotoxicity and improving therapeutic index compared with free drug. 
Also aspartate transaminase and alkaline phosphatase levels were raised in 
case of free drug whereas in case of untreated, Tuftsin micro-Amp B and micro-Amp 
B there was no significant difference observed. 
From the observations made in the present study, we infer that microsphere 
formulations of Amp B possess extra advantages over amphotericin B deoxycholate 
due to reduced toxicity, more stability and specific targeting of the drug to the site of 
infection. Further, the microsphere preparation of Amp B with immunomodulator 
tuftsin not only preserves all the advantages associated, but also activates the key 
components of the immune system (macrophages and neutrophils) for the increased 
phagocytosis of the pathogens. Therefore, the finding that the efficacy of antifiingal 
agents is increased by addition of tuftsin may be of great clinical significance in cases 
of immunocompromised persons, the main sufferers of ftmgal infections. 
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Chapter 3 
Synergistic therapeutic effect of 
liposomal nystatin with tuftsin 
liposomes encapsulated C. 
albicans cytosolic antigens in 
neutropenic mice 
3.1 Introduction 
Candida albicans is a common cause of opportunistic fungal disease in 
immunocompromised or otherwise modified host (Ashman et al, 1998). The systemic 
antifungal chemotherapeutics used for treating Candida infections are not yet 
satisfactory in terms of efficacy, toxicity, antifungal spectrum or the possibility of 
drug resistance. Moreover, there are only a few therapeutic options available for these 
infections. Severe toxicity such as impairment of renal function, limits the use of Amp 
B. Azoles (fluconazole and itraconazole) are safer, however their frequent use in 
humans has led to the development of resistant strain of Candida and there has been 
some concerns regarding emergence of cross-resistance to other chemotherapeutics as 
well (Horn et al, 1985; Thaler et al, 1988; Klein et al, 1984; Sanglard et al, 1995). 
Host defence mechanisms against C albicans infection are complex. Many 
studies have demonstrated essential roles for phagocytic cells, classical cell-mediated 
immunity, and humoral immune responses in the resolution of C. albicans infections. 
Deficiencies in any of these system lead to increased susceptibility in the host 
(Greenfield, 1992). 
Immunotherapy for prevention and treatment has less possibility of resistance 
problem, and it will be beneficial in eradicating fimgal infections from a large human 
population. In recent years, many workers have tried to develop safe and reliable 
methods to confer protection against fungal infections (Chaffin et al, 1998). 
The said vaccine with all requisite properties is the dire need of hour in order 
to get protective immunity against fungal infections. Many studies have revealed that 
some immunogenic molecules present in the Candida impart anticandida resistance to 
the host. These molecules include- cell wall polysaccharides, mamian or 
mannoproteins (Jouault et at, 1994), intracellular components such as ribosomes 
(Levy et al, 1985) and heat shock protein hsp 90 (Mathews et al, 1991) as well as 
antibodies to hsp90 or mannan (Han and Cutler, 1995). 
Many small peptides have established their potential as vaccine 
adjuvants/boosters and also as therapeutic agents in treatment of 
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immunocompromised conditions. For example, MDP analogs are already in use as 
immunoadjuvants for tetanus vaccine. Tuftsin, a tetrapeptide, is another 
immunomodulator, which has shown its potential in clinical trials for the inflections 
like cancer and AIDS. It has been shown to increase the efficacy of different 
liposomised-drugs used for the treatment of protozoal, bacterial and fungal infections 
in model animals (Gupta et al, 1986; Guru et al, 1989. Owais and Gupta. 2000). 
Immunotherapy with cell surface mannoproteins although found to be effective 
against systemic candidiasis, however, niost of them induce mannoproteins have non-
specific immunomodulatory or immunosuppressive functions in the host. For 
example, cell wall glucans have a variety of non-specific immunomodulatory effects. 
Therefore, cell wall components such as mannoproteins and glucans when used as 
antigen not only cause adverse effects in human; however they also hamper activation 
of immune components. Cytosolic fraction being devoid of cell wall components has 
least non-specific immunosuppressive functions thus minimizing the adverse effects 
of vaccination. Immunization with cytosolic antigen containing tuft-liposomes is not 
only activating the humoral branch of immime system but also provokes the key 
players of immune system i.e. macrophages and neutrophils for their increased 
fungicidal activity. 
The mechanism that prevents C. albicans infection in immunocompetent 
individuals is likely to involve both cell-mediated immunity and humoral immunity. 
(Plotnick and Cerri, 1957). A significant number of reports have shown that cell-
mediated immunity plays a major role in protection against candidiasis in normal 
healthy as well as in immunomodulated hosts (Mehta et al, 1987). There are also 
suggestions that specific humoral rather than cellular immunity contributes to 
anticandida protection. The elimination of fungi from the tissue of normal healthy 
objects is often associated with natural co-operativity among the cells of immune 
response particularly cytokine mediated interaction between T-cells and phagocytes 
such as macrophages and neutrophils (^roughton et al, 1991; Chen et al, 1978). 
Indeed, it has also been demonstrated that T-cell derived cytokines such as IL-2, IFN-
y and a-TNF activates candidacidal activity of murine and human macrophages and 
neutrophils in vitro (Daniey and Hilger, 1981). In case of immunocompromised 
individuals, however, these mechanisms do not operate optimally due to fragile 
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cellular immune functions (Szabo et al, 1995). Since, these individuals are the main 
targets for fungal infections, immunization of such patients with fungal immunogenic 
molecules along with immunomodulator, which activates macrophages/monocytes for 
their normal function, should offer obvious advantages over conventional 
immunization procedures. 
The immunoadjuvant action of liposomes have been confirmed and extended 
by numerous groups for a wide spectrum of fungal, bacterial, viral, protozoan 
infections (Kubo et al, 1994; Nishioka et al, 1994; Agarwal et al, 1994). In previous 
studies, effect of a number of unique structural characteristics of liposomes on 
immune response have been investigated that eventually opened a variety of options 
in vaccine design. The rationale behind using the liposomes as a vaccine vehicle lies 
in the fact that they are avidly taken up by antigen presenting cells particularly 
macrophages for the processing and presentation of the antigen. Further, incorporation 
of some immunomodulators or immunoadjuvants such as muramyl dipeptide, 
lipopolysachharides and tuftsin in liposomes are also likely to potentiate their 
immunoadjuvant potential. 
In the present study we explored the potential of Tuft-liposomes as a candidate 
vaccine for prophylaxis of experimental murine candidiasis. Our results show that 
immunization with cytosolic antigen entrapped in Tuft-liposomes prevents systemic 
candidiasis more effectively than the other antigen-adjuvant combinations used in the 
study. Liposomal tuftsin was primarily augmenting the himioral and to some extent 
cell-mediated immune responses of antigenic components of C albicans over that of 
PC-liposomes. Chemotherapy alone cannot take care of various pathogens, in 
particular, where the mechanism of resistance is used as a defence tool to nullify the 
effect of the drug used for their elimination. In fact the immune components might 
also not be very effective when animals were exposed to high inocula of infection. 
Keeping these facts into consideration, we studied the combined synergistic effect of 
chemotherapy and immunization over that of chemotherapy or immunization alone. 
Since fungal infections are very common in leukopenic persons, in another set 
of experiment, we examined the protective role of tuftsin liposomes encapsulated with 
C. albicans cytosolic antigen in neutropenic animals. The therapeutic effect of 
nystatin in combination with immunization was also examined in severely 
neutropenic mice. 
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3.2 Material and Methods 
3.2.1 Preparation of cytosolic antigen from C. albicans 
C. albicans was cultured on YPD agar plates (yeast extract 1%, peptone 2%, 
dextrose 2%, Agar 1.5%) at 37 ° C overnight. Cells harvested by pelleting the culture 
were washed in 50mM sodium phosphate buffer containing 0.15 M NaCl as a 
stabilizer. The fungal cells were collected in lysis buffer containing 100 mM Tris-HCl 
(pH 8.0), lOOmM NaCl, (w/v), ImM EDTA and ImM PMSF. The cell suspension 
was homogenized for 15 minutes with intermittent cooling followed by sonication for 
15 min. at 4 °C by probe sonicator. The preparation was pelleted at 2000 g for 15 min. 
and the supernatant was collected. The concentration of the protein was determined 
by the BC A method of protein estimation. 
3.2.2 Preparation of dried reconstituted vesicles (DRVs) 
Dried reconstituted vesicles (DRVs) containing antigen were prepared using 
the known method (Agrewala et al, 1996). Unilamellar liposomes were prepared 
from egg PC (49 |amol) and cholesterol (21^mol) with or without tuftsin (50 
fxg/animal). Briefly, the mixture of lipids along with tuftsin was dissolved in 
chloroform and methanol. The mixture of solution of different lipids and tuftsin was 
reduced to a thin dry film in acid clean glass tube. The film was hydrated with the 
antigen solution and flash frozen. The frozen mixture was lyophilized to obtain a dry 
powder. The dried powder was rehydrated with 1/10 volume of original solution of 
mixture and finally made up to the original volume with normal saline. 
The reconstituted mixture was centrifiiged at 10,000 rpm for 15 minutes at 4 
'^C in cooling centrifiage. The pellet was collected by removing the supernatant after 
two washings with normal saline. The protein entrapped in liposomes was estimated 
by BCA method (Owais et al, 2000). Briefly, the liposomes (given volume) were 
lysed with 10% Triton X-100 solution (the final concentration of Triton X-100 was 
maintained 1%). The mixture of solutions A and B of BCA reagent was added to the 
lysed liposomes (released protein) and' then incubated at 37 °C for 45 min. The 
absorbance was measured at 580 nm wavelength. The protein concentration was 
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calculated using a standard curve of OVA, which was plotted in presence of Triton X-
100 (1% final concentration). 
3.2.3 Estimation of entrapped antigen in Tuftsin bearing liposomes 
The estimation of entrapped antigen in tuftsin bearing liposomes was 
determined by conjugating the antigen with Fluorescein isothiocynate (FITC) 
(Konnings et al, 2002). The cytosolic fraction of Candida antigen was conjugated 
with FITC by following published procedure. Antigen solution of 2 mg/ml was 
prepared in 0.1 M sodium carbonate buffer of pH 9.0. The FITC (1 mg/ml dissolved 
in DMSO) was mixed with protein in the ratio of 1.0 ml. of protein and 50 ^1 of FITC 
solution. The dye was added very slowly in 5^1 aliquots and protein solution was 
gently and continuously stirred during the addition. After the addition the mixture was 
incubated for 8 hours at 4 ''C. The unreacted FITC was separated from the FITC-
protein conjugate by gel filtration. The ratio of fluorescein associated with protein 
was estimated by measuring the fluorescence at 495 nm and protein content by 
measuring absorbance at 280 run. 
3.2.4 Liposome Preparation 
Unilamellar liposomes were prepared from egg PC (49 (imol) and cholesterol 
(21 ixmol) with or without tuftsin (7-8% by PC weight) following published procedure 
(Owais et al, 1993). Briefly, the mixture of lipids and Nystatin (in ratio of 40.T w/w) 
along with tuftsin was dissolved in methanol and chloroform. The mixture of different 
lipids. Amp B and tuftsin was reduced to a thin dry film, in acid clean glass tube. 
Finally, the traces of the organic solvents were removed by subjecting the flask to 
vacuum overnight at 4 °C. The dried lipid film was hydrated with 150-mM sterile 
saline, followed by sonication for 1 hour at 4 °C under N2 atmosphere in bath type 
sonicator. The sonicated preparation was centrifuged at 10,000 g for 1 h at 4 °C to 
remove un-dispersed lipid and extensively dialysed against saline for 24 hour at 4 °C 
in the dark to separate free drug from the liposomal preparations of Nystatin. The 
tuftsin bearing liposomal preparation of Nystatin was found out to be of unilamellar 
type with size range of 80 ± 10 nm as revealed by electron microscopy. 
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3.2.5 Immunization 
Specific pathogen free Balb/c mice were intraperitoneally immunized with an 
initial injection of antigen (100 )Lig/animal (0.2 ml)) in different liposomal 
formulations. Same amount of antigen emulsified in IFA was also injected in the 
animals of one of the experimental groups. Further, mice received two booster 
injections of antigen (50 |ag/animal) on days 14 and 21 in same liposomal 
combinations. The animals were divided into the following groups: 
1. Saline 
2. Tuft-lip 
3. IF A-Antigen 
4. Lip-Antigen 
5. Tuft-lip-Antigen 
3.2.6 ELISA 
The animals from various groups were bled through ocular puncture on day 4 
after final booster. The blood was allowed to clot and serum was separated by 
centrifiigation at 1500 rpm for 10 minutes. Each well of ELISA plate was coated with 
500 ng of antigen prepared in bicarbonate buffer (50 mM, pH 9.6) for 4 hours at 37 
C. The antigen-coated wells were extensively washed with 20 mM Tween-Phosphate 
buffer saline (150 mM NaCl, 0.1% Tween-20). The wells were blocked by skimmed 
milk (5% in bicarbonate buffer) by pouring milk upto the top of the well for overnight 
at 4 °C. Next day, the wells were thoroughly washed with T-PBS with 3 slow (5 min.) 
and 3 fast washings. The wells were loaded with antigen specific sera (Primary Ab) 
diluted serially upto 80,000 dilutions. The plate was incubated with 1° Ab at 37 °C for 
4 hours. After incubating the plate with antigen specific sera, it was again washed 
with Tween-PBS. Now, the ELISA plate was finally incubated with HRP conjugated 
anti-mouse IgG (2° Ab) at 37 °C for 1 hour. After incubating with 2° Ab the plate was 
again extensively washed with T-PBS. At last, substrate (TMB, 100 ^1) was added to 
each well in dark and incubated for 5 minutes. The reaction was stopped with 7% 
H2S04 (50 1^1) and plate was read at 450 nm in ELISA reader. 
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3.2.7 Determination of antigen specific IgG isotypes 
The production of antigen specific antibodies was measured in the sera of 
mice belonging tovarious different experimental groups (Agrewala et al, 1996). The 
animals were injected with two doses of free antigen, or antigen entrapped in the egg 
PC/Chol or egg PC/ Choi /Tuft liposomes (50 fag/ animal) on day 0 and 14 and 21 and 
were bled 4 days later to monitor the presence of antibodies. Ninety six-well 
microtiter plates (Costar, Boston, MA) were coated overnight with 50 ^l of antigen 
(0.5 ng / well) in carbonate-bicarbonate buffer, 0.05M, pH 9.6 at 4°C. After extensive 
washing with PBS-Tween 20 buffer, 300 \xl of blocking buffer (3% skimmed milk in 
PBS-Tween 20) was applied to the wells and incubated at 37 °C for 90 min. The 
blocking buffer was removed and log 2 dilutions of test and control sera were added. 
The reaction was allowed to proceed at 37 °C for 2 h. The microtiter plates were 
washed and 50 fil of biotinylated goat anti-mouse IgGl and IgG2a Abs were added. 
The plates were incubated at 37 °C for 1 h. After usual steps of washings, 50 JJI of 
streptavidin-HRP was added in each well and the plates were incubated at 37 °C for 1 
h. The plates were washed once again before adding 50 \il of orthophenylene diamine 
dihydrochloride (0PD.2HC1) and were finally incubated at 37 °C for 20 min. The 
reaction was terminated by the addition of 50 |il of 7% H2SO4. The absorbance was 
read at 492 nm with microplate reader (Eurogenetics, Torino, Italy). Antibody titers 
were expressed as the highest dilution of serum that yielded an O.D. of 0.2 above the 
control wells (i.e. animals injected with PBS alone). 
3.2.8 Isolation of antigen specific T cells 
The animals were immunized either with free cytosolic antigen or after its 
entrapment in tuft free or tuft bearing egg PC/ChoI liposomes (100 fig 
antigen/animal). On day 7, the animals were sacrificed and their spleens were taken 
out aseptically and T cells were isolated. A single cell suspension of mice spleens was 
prepared in HBSS. The erythrocytes were lysed by the hemolytic Gey's solution (3ml 
per spleen) by incubating for 10 min. on the ice (Mishell and Shiigi, 1980). The cells 
were then washed three times with RPMI-1640. The resulting cell suspension was 
incubated at 37 °C in 7% CO2 in tissue culture dishes for 1-2 h to facilitate the 
adherence of the macrophages. The non-adherent cells were incubated with nylon 
wool column for 1 h at 37 °C in 7% CO2. The cells eluted from the column were 
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incubated with a cocktail of anti-Mac3 Ab, anti-I Ad and anti-IgM Ab at 4 °C for 45 
min. The cells were washed and then treated with baby rabbit complement for 30 min 
at 37 °C. The cells were once again washed with RPMI-1640 and then used as an 
enriched source of T cell population. 
3.2.9 T cell proliferation assay 
The T cell proliferation experiment was performed following published 
procedure (Agrewala et al, 1996). Briefly, the T cells (2x 10'^ /well) obtained from 
different groups of mice (i.e. animals immunized with free antigen, antigen 
encapsulated in egg PC/Chol liposomes, antigen encapsulated in Tuft-Egg PC/Chol 
liposomes and PBS) were cultured in triplicate wells. The cells were incubated with 
macrophages (6 x lO'^ /well) pulsed with different doses (0.001-100 jig/ml) of free or 
liposomised antigen. The macrophages were treated with Mitomycin C (50 jig/ml). 
The cultures were incubated for 72 h at 37 °C / 7% CO2. The cells were pulsed with 
1.0 [iCi [^H]-thymidine for 16h before harvesting by automatic cell harvester 
(Skatron, Tranby, Norway). The [ H]-thymidine incorporation was measured by 
standard liquid scintillation counting method. The results are expressed as mean cpm 
of triplicate cultures. 
3.2.10 Isolation and culture of peritoneal exudates macrophages 
Collection of Peritoneal Exudate Cells (PECs) 
I. PECs were collected from thioglycolate treated animals. At each time point 2-
3 mice were sacrificed. 
II. The animals were injected i.p. with 5ml (ice cold) of RPMI incomplete 
medium containing antibiotics and antimycotic mix as well as heparin (5U/ml) and 
syringe was left as such. 
III. The abdomen was gently mashed and the medium containing PECs was 
lavaged out in siliconised 15 ml glass tubes. 
The cells were washed 3 times with RPMI incomplete medium by 
centrifiigation (1000 rpm, 10 min at 4 °C) and resuspended. The suspension was 
.65 
brought to the final cone, of 3x10^ cells /ml in Complete RPMI supplemented with 
10% FCS (heat inactivated) and antibiotic as well as antimycotic mix. 
3.2.11 Preparation of fungal cells for infection 
C. albicans (preserved in 10% glycerol at -20°C) was cultured in 5% dextrose 
at 37 °C for 24 hours and pelleted at 2000 g at 4 °C. The cells were counted by 
hemocytometer and diluted with normal saline in such a way that each 200|.il contains 
7x10^ cells required for challenging one animal. 
3.2.12 Cyclophosphamide induced immunosupression 
The animals were made Leukopenic throughout the course of study by 
injecting cyclophosphamide (250 mg/kg) intraperitoneally (i.p.) according to the 
following schedule. Mice received three CY injections 4 days before each 
immunization and 3 days before the infection with 5 x 10^  C albicans cells. 
3.2.13 Treatment with liposomal nystatin and its combination with immunization 
The combined therapeutic effect of liposomal nystatin and immunization was 
examined as follows. Each mouse iimnunized with different liposomal forms of 
cytosolic antigen of C. albicans or IFA-Ag emulsion or saline, was infected 5x10^ 
CPU of C. albicans 1 week after the last booster and then treated with nystatin at the 
described doses and schedule. Nystatin was incorporated into the liposomes (PC/ 
Choi: 7/3) and the drug formulation was given through i.p. route at the dose of 3 
mg/kg (0.2 ml.) on days I and 5 post infection. The animals were divided into the 
following groups: 
(1) Saline 
(2) Tuft-lip 
(3) Lip-nystatin (3 mg/kg) 
(4) IFA-Ag (+) lip-nystatin (3 mg/kg) 
(5) Lip-Ag (+) lip-nystatin (3 mg/kg) 
(6) Tuft-lip-Ag (+) lip-nystatin (3 mg/kg) 
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3.2.14 Chemotherapy of immunized neutropenic mice by liposomal nystatin 
The efficacy of tuftsin in protection against systemic candidiasis was analyzed 
by immunization of neutropenic mice, alone or in combination with chemotherapy. 
The chemotherapy was started after 24 hours of infection with C. albicans spores (7 x 
10^  cfu/mouse). Mice were divided into the following groups with proper control: 
(1) Saline 
(2) Tuft-lip 
(3) Lip-nystatin 
(4) IFA-Ag 
(5) IFA-Ag (+) lip-nystatin 
(6) Lip-Ag (+) lip-nystatin 
(7) Tuft-Ag 
(8) Tuft-Ag (+) lip-nystatin 
3.2.15 Assessment of resistance and susceptibility to disseminated candidiasis in 
immunized mice. 
To determine relative susceptibility or resistance of immunized animals to C. 
albicans infection, the survival rate data and total fiingal load in different organs was 
analyzed. For the assessment of ftmgal load, three mice from each group were 
sacrificed on day 5'** post infection. 
67 
Results 
3.3 Results 
3.3.1 Animals immunized with Tuft-lip-Ag show higher antibody titer 
Antibody response against liposomal preparations of antigen as well as Ag-
IFA combination was demonstrated in the sera of immunized animals. Our results 
clearly indicate higher antibody titer in the animals immunized with antigen 
containing Tuft-liposomes as compared to the control (Fig. 12). Among various 
controls, the Egg PC-liposomes were found to be more effective in inducing the 
antibody response followed by Ag-IFA emulsion. This indicates that Tuft-liposomes 
are the most effective in stimulating the antibody secreting cells. 
3.3.2 Tuftsin bearing liposomes increase the secretion ratio of IgG2a/IgGl isotype 
The impact of the immunization with the antigen entrapped in the tuftsin 
bearing liposomes was monitored for the generation of antigen reactive IgGl and 
IgG2a isotypes in the sera of the animals inoculated with the antigen entrapped in the 
different types of liposomes. Our results show the significant increase in the secretion 
ratio of IgG2a/ IgGl type of antibodies in the sera of animals immunized with antigen 
entrapped in the Tuft-liposomes (Fig. 13). Besides, the overall production of the 
antibodies was also much higher in the sera of animals immunized with tuftsin 
bearing liposomes as compared to the animals of the other groups (Fig. 12). No IgGl 
and IgG2a-isotypes were detected in the control groups injected with either plain Tuft 
egg PC/Chol, or plain egg PC/Chol liposomes (no antigen) or PBS. 
3.3.3 Antigen containing Tuft-liposomes enhances proliferation of antigen specific T 
cells 
The stimulatory potential of Lip-tuftsin encapsulating C albicans cytosolic 
antigen was analyzed on the proliferation of the antigen specific T cells (Fig. 14). The 
T cells of the mice immunized with Tuft-lip-antigen shows significantly higher 
proliferation as compared to the T cells obtained from the animals immunized with 
egg PC/Chol vesicles containing antigen. The antigen (l}xg/ml) entrapped in tuftsin 
containing liposomes could bring about 44642 ± 3420 cpm, thymidine incorporation, 
a parameter to study T cell proliferation. In contrast, liposomes prepared of egg 
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Fig. 12 Antibody response in mice immunized with liposomal forms of cytosolic 
fractions of C albicans. Results are expressed as mean of responses of five mice in 
each group ± S.D. The figure is representative of three different experiments. 
a 
d 
0 
Saline Tuft-lip IFA-Ag Lip-Ag Tuft-lip-Ag 
Group 
IFA-Ag vs Tuft-Iip-Ag 
Lip-Ag vs Tuft-lip-Ag 
P value 
0.011 
0.016 
Fig. 13 Antibody isotyping response in mice immunized with liposomal forms of 
cytosolic fractions of C. albicans. Results are expressed as mean of responses of five 
mice in each group ± S.D. The figure is representative of three different experiments. 
Tuft-lip-Ag Lip-Ag 
Group 
Tuft-lip-Ag vs Lip-Ag 
P value 
<0.0124 
Fig. 14 Antibody incorporated in Tuft-Iiposomes augmented the proliferation of 
antigen specific T cells. PBS (•), Free Antigen (o), Lip-Antigen (V), Tuft-lip-
Antigen (A). Results are expressed as mean of responses of five mice in each group ± 
S.D. The figure is representative of three different experiments. 
0.001 0.01 0.1 1 
Antigen (^g/ml) 
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PC/Chol vesicles could induce only 20888 ± 1280 cpm with equal concentration of 
antigen. T cells responsiveness to antigen was observed in a dose dependent manner. 
The control cultures containing the cells obtained from either antigen-unimmunized 
animals or immunized with PBS could not incorporate much (<2000 cpm) of H-
thymidine. 
3.3.4 Tuftsin-lip-antigen immunized mice have increased survival rates 
The cytosolic fraction of C. albicans cell extract encapsulated in Tuft-
liposomes prolonged the survival time of the infected animals remarkably when 
compared to animals from other groups in the experiment (Fig. 15). Immunization of 
animals with Tuft-lip-antigen offered more protection against C. albicans infection 
and percent survival of animals was found 60 % observed on day 40 post-infection. 
While only 30 % animals survived in the group of animals immunized with PC-lip-Ag 
combination and 20 % from those of animals that received Ag-IFA emulsion. The 
mean survival time was also found much-increased in animals of group vaccinated 
with Tuft-lip-Ag than the animals of all other control groups (Table 5). 
Table 5 Mean survival time of immunized mice after infection with 
C. albicans 
Group 
Control 
Tuft-lip 
IFA-Ag 
Lip-Ag 
1 Tuft-lip-Ag 
Fungal Load 
(CFU/ml ± S.D.) 
Mean survival time ± S.D. 
5.6±1.1 
8.8 ±1.8 
>18.8±3.6 
>26.4±6.4 1 
> 36.8 ±10.2 
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Fig. 15 Survival of mice immunized with various adjuvant-antigen combinations 
followed by chemotherapy after infection with C albicans. Saline (•), Tuft-lip 
(o), IFA-Ag (T) , Lip-Ag (A), Tuft-Iip-Ag (•). Ten mice were taken in each group 
and experiment was repeated three times. 
4 6 8 10 15 20 25 30 40 >50 
Days post infection 
Group 
Tuft-lip-Ag vs IFA-Ag 
Tuft-lip-Ag vs Lip-Ag 
Lip-Ag vs IFA-Ag 
P value 
0.054 
0.561 
0.252 
3.3.5 Antifungal activity of Lip-nystatin increases when preceded with Tuft-lip-Ag 
immunization 
Immunization of animals with antigen entrapped in Tuftsin bearing liposomes 
confers higher resistance against systemic candidiasis both in terms of survival as well 
as CFU in the kidneys. The survival of the animals was further increased when 
liposomal nystatin even at the lower doses (3 mg/kg) was given to the immunized 
animals. The combination of immunotherapy and chemotherapy was found to be 
synergistic and therefore more effective in reducing the severity of the infection. The 
Tuftsin-Ag immunized animals treated with two doses of liposomal nystatin on the 
days 1 and 4 after infection have maximum survival time -100% followed by Lip-Ag 
immunization plus Lip-nystatin treatment (60%). On the contrast, the animals treated 
with only Lip-nystatin have only 20% survival (Fig. 16). The mean survival time was 
also increased significantly than the corresponding groups of animals without 
chemotherapy (Table 6). 
3.3.6 Fungal burden in Kidney 
Severity of the C. albicans infection among different groups was fiirther 
confirmed by the assessment of the colony forming units (CFU) data in systemic 
circulation and kidney of the infected animals. CFU count determined on day 7 post-
infection was found least in kidney of animals (23,640 + 2,994)) immunized with 
Tuft-lip-Ag followed by animals of groups vaccinated with PC-lip-Ag (43,556 + 
4,316)) and IFA-Ag emulsion (60,444 ±5,333)) respectively (Table 7). The animals 
survived fi-om the group immunized with antigen encapsulated in Tuft-liposomes 
were further screened for CFU count in their kidney on day 50 post-infection. The 
CFU count per kidney was found 372, 418 and 212 respectively. 
In the second set of experiment, the animals were treated with liposomal 
nystatin (3 mg/kg) after immunization with different liposomised forms of cj^osolic 
antigen of C. albicans. The CFU load determined in the kidney of animals on day 7 
postinfection show increased efficacy .of the liposomal nystatin in the group of 
animals immunized with Tuftsin bearing liposomal antigen followed by that of PC-Ag 
and Lip-nystatin combination. Whereas the animals treated with liposomised nystatin 
that was not preceded by immunization show severe infection as reflected by CFU 
load in their kidney (Table 8). 
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Fig. 16 Survival of mice immunized with various adjuvant-antigen combinations 
followed by chemotherapy after infection with C albicans. Control (•), Tuft-lip 
(o), Lip-Nys (T) , IFA-Ag + lip- Nys (A), Lip-Ag + lip- Nys (•), Tuft-lip-Ag + lip-
Nys (D). Ten mice were taken in each group and experiment was repeated three 
times. 
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I 
Days Post infection 
Group 
IFA-Ag + Lip-Nys vs Tuft-Ag + Lip-Nys 
Lip-Ag + Lip-Nys vs Tuft-Ag + Lip-Nys 
Lip-Ag + Lip-Nys vs IFA-Ag + Lip-Nys 
25 30 >40 
P value 
<0.001 
0.010 
0.244 
Table 6 Mean survival time of animals from different groups 
1 Fungal Load (CFU/ml + S.D.) 
Group 1 Mean survival time + S.D. 
Control 
Tuft-lip 
Lip-Nystatin 
IFA-Ag-Nystatin 
Lip-Ag-Nystatin 
Tuft-Ag-Nystatin 
6.2+1.1 1 
8.0+1.8 
>15.0 + 3.6 
>34.2 +8.4 
> 36.8+10.2 1 
>50.0±0 1 
Table 7 Fungal burden in kidney and spleen of immunized mice on day 5 
postinfection 
Treatment 
Group 
Saline 
Tuft-lip 
IFA-Ag 
Lip-Ag 
Tuft-Iip-Ag 
Fungal load (cfu/ organ) on day 5 post infection 
Kidney 
95111 + 12472 
84242+ 8987 
60444 + 5333 
43556 ±4316 
23164 + 2992 
Spleen 
64325 + 7602 
53804+5174 
31488 ±4560 
24023 ± 5394 
12230 ±3608 
Group 
IFA-Ag Vs Tuft-lip-Ag 
Lip-Ag Vs Tuft-lip-Ag 
P value 
>0.001 
>0.311 
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3.3.7 Tuftsin mediated immunization offers more protection in leukopenic mice 
Most humans harbor C. albicans as normal microbial flora or as a non-
prominent, underlying infection. Cancer Patients treated with immunosuppressive 
anti-neoplastic drugs such as cyclophosphamide develop neutropenia and often suffer 
with fungal infections. Injection of CY 3 or 4 days before each immunization induces 
severe depletion of leukocytes, the front line cells in defence against Candida 
infections. To investigate the role of tuftsin in protection against candidiasis in 
persistently neutropenic mice, cyclophosphamide was injected 3 days before each 
immunization and infection. Subsequent challenge with 5 x 10^  C. albicans cells 
caused high mortality, and all non-immunized mice died within 6 days as a result of 
systemic infection. In contrast, leukopenic mice vaccinated with tuftsin liposomal 
formulation of antigen resisted rapid infection and -20% animals survived till day 40 
of observation. On the contrary, no animal survived in any other group on day 40 
(Fig. 17). The mean survival time was found to be >17.8 days in Tuft-liposomal 
antigens vaccinated animals while it was found 7 and 7.6 days in the animals 
immunized with IFA-Ag and Lip-Ag (Table 9). 
In another set of experiment, the efficacy of Lip-nystatin was tested in the 
neutropenic mice after immunizing them with various combinations of antigen, 
including Tuftsin bearing liposomal antigen. The survival of the neutropenic mice 
immunized with tuft-lip-antigen increases significantly in comparison to mice of other 
groups after treatment with lip-nystatin- (Fig. 17). Lip-nystatin at the drug dose (3 
mg/kg) increases the survival rate upto 40% while immunized mice without 
chemotherapy have 20% survival. To increase the efficacy of the drug, it was used at 
the dose of 5 mg/kg in the treatment of the neutropenic-infected mice. Drug dose (5 
mg/kg) ftirther increases the survival of the Tuft-lip-Ag immunized animals with upto 
60% (Fig. 17). The mean survival time increases from 17.8 to 25.4 and 30.0 days in 
the Tuft-lip-antigen immunized animals after treatment with lip-nystatin at the dose of 
3 mg/kg and 5 mg/kg respectively (Table 9). 
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Fig. 17 Survival of leuckopenic mice immunized with various adjuvant-antigen 
combinations followed by chemotherapy after infection with C. neoformans. 
Saline (•), Tuft-lip (o), Lip-Nys (T) , IFA-Ag (A), IFA-Ag + lip-Nys (•), Lip-Ag + 
lip-Nys (•), Tuft-Ag (•), Tuft-Ag + lip-Nys (0). Ten mice were taken in each group 
and experiment was repeated three times. 
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2 4 6 8 10 15 20 25 30 40 >50 
Days post infection 
Group 
Lip-Nys vs IFA-Ag + Lip-Nys 
Lip-Nys vs Lip-Ag + Lip-Nys 
Lip-Nys vs Tuft-Ag + Lip-Nys 
P value 
0.479 
0.276 
0.085 
Table 8 Effect of chemotherapy on the efficacy of immunization against C. albicans 
Treatment Group 
Saline 
Tuft-lip 
IFA-Ag+lip-Nys 
Lip-Ag+Lip-Nys 
Tuft-lip-Ag+Lip-Nys 
Fungal load (cfu/ organ) on day 5 post infection 
Kidney 
102111 + 18472 
84242 + 18980 
26444 + 4333 
19556 ±3316 
5164 ±920 
Spleen 
76325 ± 12602 
55804±10174 
23488 ± 7566 
14023 + 1940 
2230 ± 508 
Group 
IFA-Ag + Lip-Nys vs Lip-Ag + Lip-Nys 
IFA-Ag + Lip-Nys vs Tuft-lip-Ag + Lip-Nys 
Lip-Ag + Lip-Nys vs Tuft-lip-Ag + Lip-Nys 
P value 
>0.072 
>0.001 
>0.001 
Table 9 Mean survival time of neutropenic mice from different groups 
Group 
Saline 
Tuft-lip 
Lip-nystatin 
IFA-Ag 
IFA-Ag (+) lip-nystatin 
Lip-Ag 
Lip-Ag (+) lip-nystatin 
Tuft-lip-Ag 
Tuft-Ag (+) lip-nystatin (3mg/kg) 
II Tuft-Ag (+) lip-nystatin (5 mg/kg) 
Fungal Load (CFU/ml j^S.D.) 
Mean survival time + S.D. 
2.8 + 0.6 
4.8 + 1.5 
6.6 + 2.1 
7.0 + 2.4 
> 15.2+ 5.6 
7.6 + 2.8 
> 18.0 + 4.8 
> 17.8+ 6.2 
> 25.4+ 7.2 
> 34.0+10.2 
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3.3.8 Fungal load in kidney and spleen of leukopenic mice 
The severity of the infection was further monitered by assessment of fungal 
burden in the organs of the infected mice on day 5. A very high CFU count was found 
in the kidney and spleen of unimmunized mice infected with 7 x 1 0 ^ cells. The 
numbers of C. albicans cells were found least in the Tuft-lip-Ag immunized animals 
than the animals immunized by other antigen-adjuvant combinations. The CFU count 
was further reduced when chemotherapy was administered in combination with 
immunization. Liposomal nystatin in combination of immunization, at the dose 5 
mg/kg shows better results in terms of fungal burden both in kidney and spleen 
(Table 9). 
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3.4 Discussion 
Liposomes have been exploited for designing safe and efficacious vaccines 
against many viral, bacterial and protozoan diseases (Van Rooijen, 1995). In addition 
to their function as carrier or depots for antigens, liposomes effectively enhance the 
uptake and presentation of antigen by macrophages and dendritic cells leading to 
stimulation of T lymphocytes (Van Rooijen, 1993). 
Since elimination of macrophages increases the susceptibility of animals to 
candidiasis, it suggests that macrophages play a very important role in the resistance 
against candidiasis (Qian et ai, 1994). Macrophages are able to kill C. albicans 
through several effector pathways, and their candidacidal potential can be enhanced by 
activation with a number of different cytokines. Upon contact with the fungus, 
effector macrophages and neutrophils rapidly activate oxidative and nonoxidative 
pathways of killing through phagocytic and nonphagocytic mechanisms (Odds, 1988) 
Tuftsin potentiates the immunogenic capacity of the macrophages transforming some 
weak immunogens into potent immunogens (Siemion and Kluczyk, 1999). Tuftsin 
also stimulates IL-1 production by human mononuclear cells helping in maturation 
and clonal expansion of B cells (Siemion and Kluczyk, 1999), which converts into 
the plasma cells for antibody secretion. The results of the present study clearly 
demonstrated high antibody titer in the sera of animals immunized with antigen 
containing Tuft-liposomes. 
T lymphocytes have been implicated in recovery from systemic, 
gastrointestinal, and oral infections with C. albicans (Farah et al, 2001). The natural 
co-operativity among the cells of immune system, particularly cytokine mediated 
interaction between T cells and phagocytes such as neutrophils and macrophages, 
makes it logical to postulate that T-cell mediated immunity contributes significantly 
in the generation of an effective immune response against C. albicans infection 
(Farah et al, 2001). Since ftingal cells stimulate IFN-y release from T cells, it 
suggests that fungi may follow some strange way to interact with T-cells. From the 
results of present study, it is clear that liposomised-tuftsin augments the antigen 
specific T- cell proliferation. Thus increased anticandidal activity of tuftsin may also 
be attributed to its T-cell stimulating property. 
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It is well established, by both clinical and experimental studies, that either 
quantitative or qualitative neutrophil defects are a predisposing factor to disseminated 
candidiasis and that depletion of neutrophils significantly increases the susceptibility 
to systemic candidiasis (Fulurija et al, 1996; Romani et al, 1997). An important 
immunoregulatory role in fungal infections has also recently been attributed to 
neutrophils. By producing directive cytokines such as IL-10 and IL-12, these cells 
influence Th cell development as evidenced by the inability of Candida infected 
neutropenic mice to mount protective Thl response, such a response including the 
anti-fungal effector functions of macrophages could be restored by replacement 
therapy of IL-12. Therefore, the ability of neutrophils to participate in Th selection in 
fungal infections may also include a permissive role on the antifungal effector and 
immunomodulatory functions of macrophages. It has been reported that incorporation 
of tuftsin into liposornes bilayer specifically addresses the liposomes to the 
neutrophils. Non-specifically activated candidicidal cells i.e. granulocytes and 
monocytes are crucial for successful defence against systemic candidiasis. 
In addition, tuftsin increases the secretion of IgG2a/IgGl isotypes in the sera 
of immunized mice (Fig. 13). Increase in IgG2a isotype suggests the Thl/Th2 
polarization in favor of cell-mediated immune responses. This study clearly suggests 
that tuftsin bearing liposomes are successfiil in provoking antigen specific humoral as 
well as cell-mediated immunity. 
Furthermore, tuftsin enhances phagocytic and tumor necrosis factor (TNF) 
release of human kupffer cells (Siemion and Kluczyk, 1999). TNF plays important 
role in the development of protective immunity against fungal infections. Tuftsin in 
presence of antigen induces phagocytic cells for IL-6 secretion that directly affects the 
subsequent T-cell responses to C.albicans. 
Tuftsin-macrophage interaction results into activation of macrophages 
expressing nitric oxide (NO) synthase to produce NO. Murine peritoneal macrophages 
activated by tuftsin were able to kill the intracellular protozoan Leishmania major 
(Siemion et al, 1999). The non-specific activated macrophages will generate 
resistance to candidiasis similarly to that induced by live attenuated C albicans cell. 
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In the present study Tuft-liposomes containing cytosolic antigen of C. 
albicans have been used for immunization against systemic candidiasis in Balb/c 
mice. This work provides strong evidence of higher immunoadjuvant action of 
liposomes upon incorporation of tuftsin, which preferentially stimulates different 
types of immune, cells e.g. macrophages and neutrophils. This leads to the difference 
in immune responses against the given antigen. 
77 
Chapter 4 
Potential of Uposome-based 
vaccine against C. neoformans 
in immunosuppressed 
condition. 
4.1 Introduction 
There is a great deal of interest in developing an effective measure to activate 
immune mechanism that ensues the control of various infectious diseases. Unlike their 
counterparts, the control of intracellular pathogens could be made possible by 
concomitant involvement of both €04"^ and CD8"^  T cells. The helper T cells further 
segregate into dichotomous cytokine' secreting phenotypes (Gianfranco and 
Rotnagnani, 1994). Thl cells secreting gamma interferon (IFN-y), interleukin-2 (IL-
2), and lymphotoxin induce cell- mediated immunity, whereas Th2 cells producing 
IL-4, IL-6, IL-10 to facilitate B cell mediated antibody production. 
The success of vaccine depends on two key aspects: identification of specific 
antigenic targets and its ability to evoke strong and appropriate immune response. 
Over the past few decades, considerable progress has been made in identification, 
purification and synthesis of key antigenic determinants of pathogens and tumours. 
However, most of the proteins and peptide when used in purified form show weak 
immunogenicity, limiting their ability to induce a strong protective immune response. 
Co-administration of antigen with immunostimulatory adjuvants leads to the 
development of antigen specific strong immune response (Audibert and Lise, 1993; 
Richards et al, 1998). Adjuvants components of vaccine formulation should display 
universal properties of facilitating strong and sustained immunes response against 
varied immunogens as well as driving the response in appropriate direction to provide 
protective immunity. Many adjuvants have undesirable side effects that preclude their 
use in humans. Indeed, the only adjuvants currently approved for humans are alum, 
which is relatively weak potentiator of cell-mediated immune response (Gupta and 
Siber, 1995). Liposomes have been explored as possible antigen vehicles, and a 
liposome-based vaccine against hepatitis A has been licensed for use in humans 
(Gregoriadis, 1994; Gupta et al, 1993; Alving, 1995). 
However, liposomes based vaccines generally change physico-chemical 
properties of antigen and also affect their release pattern and delivery to antigen 
presenting cells. It is customary to include Lipid A or MDP or cholera toxin to elicit 
for effective immunity against given pathogen (Bennett-Guerrero et al, 2000). A 
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major rationale for using liposomes as carrier of vaccine is that macrophages or other 
antigen presenting cells promptly take up them, which is crucial for effective and 
constitutive antigen presentation (Gregoriadis, 1990; Nicholas and Jones, 1986). 
Liposome-encapsulated antigens can be immunologically presented to T cells by 
peritoneal exudate cells (containing both B and T cells and macrophages). 
Infections in patients with impaired immunity present a formidable challenge 
to the scientific community. The course of infections in these individuals is generally 
more aggressive than their normal counterparts. Also, antimicrobial therapy can be 
proved less effective in treatment of various infections in immunodebilitant 
individuals, because the contribution of underlying host defense mechanisms is very 
poor (Wey et ai, 1988). Many infections in these patients are incurable despite the 
administration of microbicidal therapy; e.g., infections with the fungi C. neoformans, 
C. albicans, Histoplasma capsulatum and A. fumigatus are difficult to cure in patients 
with AIDS (Viviani, 1992; Warnock, 1998). They can be suppressed with powerful 
antifungal drugs in higher doses, but lifelong suppressive therapy is required to 
prevent relapses. These persons due to their fragile immune system and impaired 
physiological processes carmot tolerate toxic antifungals in higher doses for a very 
long time. This phenomenon results into very high frequency of toxic manifestations, 
which lead to the collapse of many vital physiological processes. 
Some infections in immunocompromised hosts with impaired immunity, e.g., 
those caused by Streptococcus pneumoniae, may be of similar severity to the infection 
that occurs in normal subjects, however they may be recurrent and necessitate 
frequent courses of antibiotic therapy. In this regard, the extensive use of antibiotics 
for treatment and prophylaxis in patients with impaired immunity may be playing a 
role in the emergence of drug-resistant organisms (Ghannoum and Rice, 1999). 
Keeping into consideration the fact that the licensed vaccines in practice were 
developed for administration to individuals with normal immunity. Besides, the 
assessment of their efficacy was carried out exclusively in normal hosts. Therefore, 
there are many unresolved questions about the feasibility of using existing vaccines to 
prevent infectious diseases in patients with impaired immunity (Pirofski and 
Casadevall, 1998). Active immunization in the form of vaccine is an ideal strategy 
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for prevention of infectious diseases among high-risk patients. For example C. 
neoformans polysaccharide-based vaccines have always had poor immunogenicity. 
However, a cryptococcal GXM-tetanus toxoid conjugate has now been developed 
which appears to be highly immunogenic and show protection in murine model 
(Murphy et al, 1998). A major concern about the patients at the highest risk for such 
infections is their immunosuppressed condition, which not let them to mount adequate 
immune response against the vaccine. Thus a vaccine for immunosuppresed persons 
may be proved successful only when it can rejuvenate immune system of the host to 
the normal healthy state. 
Present work was aimed to assess the potential of liposome-based vaccines as 
carrier of vaccine against C. neoformans infection in immunosuppressed conditions. 
Among various immunoadjuvants Tuft-lip-Ag immunized mice show strong immune 
response in terms of antibody titre. In addition, antigens entrapped in tuftsin bearing 
liposomes impart greater protection against C. neoformans infection in both 
immunocompetent and leukopenic mice. 
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Materials and Methods 
4.2 Materials and Methods 
All the reagents used in the study were of the highest purity available. Egg PC was 
isolated and purified according to published procedure (Singleton et al, 1965) as 
described before. 
4.2.1 Animals. Female Balb/C mice weighing 20 ± 2 g were used in the study. 
4.2.2 Preparation of cytosolic antigen from C. neoformans 
C. neoformans was cultured on YPD agar plates (yeast extract 1%, peptone 
2%, dextrose 2%, Agar 1.5%) by overnight incubation at 37 ''C. Cells harvested by 
centrifugation were washed in 20mM sodium phosphate buffer containing 0.15 M 
NaCl as a stabilizer. The fungal cells were collected in lysis buffer containing 100 
mM Tris-HCl (pH 8.0), lOOmM NaCl, (w/v), ImM EDTA and ImM PMSF. The cell 
suspension was homogenized for 15 minutes with intermittent cooling followed by 
sonication for 15 min. at 4 °C by probe sonicator. The preparation was pelleted at 
5000 g for 15 min. and the supernatant was collected. The concentration of the protein 
in the supernatant was determined by the method of Lowry et al (Lowry et al, 1952). 
4.2.3 Preparation of antigen containing DRVs 
Dried reconstituted vesicles (DRVs) containing cytosolic antigen of C 
neoformans were formed using the known method (Agrewala et al, 1996). 
Unilamellar liposomes were prepared from egg PC (49 fimol) and cholesterol 
(21[imol) without or with tuftsin (50 ^g/animal). Briefly, the mixture of lipids along 
with tuftsin was dissolved in chloroform and methanol (1:1). The mixture of solution 
of different lipids and tuftsin was reduced to a thin dry film in acid clean glass tube. 
The lipid film was hydrated with the normal saline and was mixed with antigen. The 
antigen solution with liposomes was freezed and thawed followed by lyophilization to 
obtain a dry powder. The dried powder was rehydrated with 1/10 volume of original 
solution of mixture and finally made up to the original volume with normal saline. 
The reconstituted mixture was centrifuged at 10,000 rpm for 15 minutes at 4 °C in 
cooling centriftage. The collected pellet was washed after removing the supernatant. 
The protein entrapped in liposomes was estimated by BCA method (Owais and 
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Gupta, 2000). Briefly, the liposomes (given volume) were lysed with 10 % Triton X-
100 solution (the final concentration of Triton X-100 was maintained 1%). The 
mixture of solutions A and B of BCA reagent was added to the lysed liposomes 
(released protein) and then incubated at 37 "C for 45 min. The absorbance was 
measured at 580 nm. The protein concentration was calculated using a standard curve 
of OVA, which was plotted in presence of Triton X-100 (1% final concentration). 
4.2.4 Estimation of antigen entrapped in Tuftsin liposomes 
Antigen was estimated by conjugating it with FITC as described in previous section. 
4.2.5 Immunization 
Specific pathogen free Balb/c mice were intraperitoneally immunized with an 
initial injection of antigen (100 |Lig/animal (0.2 ml)) in different liposomal 
formulations. Same amount of antigen emulsified in IFA was also injected in the 
animals of one of the experimental groups. Further, mice received two booster 
injections of antigen (50 |ag/ml) on days 21 and 28 in identical way. 
4.2.6 Induction of immunosupression in immunized mice 
Mice received three cyclophosphamide (250 mg/kg) injections 4 days before 
each immunization and 3 days before the infection as described before. 
4.2.7 Determination of antigen specific antibody titer by ELISA 
The blood was collected from the animals on day 4 after final booster. The 
blood was allowed to clot and serum was separated by centrifiigation it at 2000 rpm 
for 15 minutes. The generation of antigen specific antibodies was measured in the sera 
of mice immunized with cytosolic antigen of C. neoformans. An ELISA plate was 
coated with 100 \i\ of antigen solution (5|j.g/ml) in 50 mM carbonate-bicarbonate 
buffer, pH 9.6 at 4 °C. After extensive washing with PBS-Tween 20, each well was 
completely filled with blocking buffer (3% skimmed milk in carbonate-bicarbonate 
buffer) and plates were incubated at 37 °C for 4 hours. After removing the blocking 
buffer, serially diluted test and control sera were added and binding allowed 
proceeding at 37''C for 4 hours. The microtitre plates were washed and incubated with 
100 \i.\ of HRP conjugated rabbit anti-mouse IgG at 37 °C for 1 h. After the usual 
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washing steps, the peroxidase reaction was initiated by the addition of the substrate 
tetramethyl benzidine/HaOa, stopped by the addition of 4.0 N H2SO4 after 5 minute 
and absorbance at 450 nm measured in an ELISA reader. 
4.2.8 Determination of antigen specific IgG isotypes by ELISA 
The production of antigen specific antibodies was measured in the sera of the 
different groups of mice according to published procedure (Agrewala et al, 1996). 
4.2.9 Infection 
C. neoformans cells were grown in YPD at 37 °C prior to the infection. The 
animals were challenged with 7 x 10^  viable Colony Forming Units (CPU) of C. 
neoformans suspended in 0.2 ml of normal saline through i.v. route. 
4.2.10 Treatment with liposomal nystatin and its combination with immunization 
The combined therapeutic effect of liposomal nystatin eind immunization was 
examined as follows. Mice immunized with various liposomal formulations of 
cytosolic antigen of C. neoformans or IFA-Ag emulsion or saline, were infected 7 x 
10^  viable cells of C. neoformans 1 week after the last booster and then treated with 
nystatin according to described doses and schedule. Nystatin was incorporated into 
the liposomes (PC/ Choi: 7/3) and the drug formulation was given through i.p. route at 
the dose of 3 mg/kg (0.2 ml.) on days 1 and 5 post infection. The animals were 
divided into the following groups: 
(1) Saline 
(2) Tuft-lip 
(3) Lip-nystatin (3 mg/kg) 
(4) IFA-Ag (+) lip-nystatin (3 mg/kg) 
(5) Lip-Ag (+) lip-nystatin (3 mg/kg) 
(6) Tuft-lip-Ag (+) lip-nystatin (3 mg/kg) 
4.2.11 Chemotherapy of immunized neutropenic mice by liposomal nystatin 
The efficacy of tuftsin in protection against systemic cryptococcosis was 
analyzed by immunization of persistently neutropenic mice, alone or in combination 
with chemotherapy. The chemotherapy was started after 24 hours of infection with C. 
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neoformans spores (7 x 10^). Mice were divided into the following groups with proper 
control: 
(1) Saline 
(2) Tuft-lip 
(3) Lip-nystatin (5 mg/kg) 
(4) IFA-Ag 
(5) IFA-Ag (+) lip-nystatin 
(6) Lip-Antigen 
(7) Lip-Ag (+) lip-nystatin 
(8) Tuft-Ag 
(9) Tuft-Ag (+) lip-nystatin 
4.2.12 Susceptibility assessment of C neoformans infection to nystatin in immunized 
mice 
To determine relative susceptibility or resistance to C. albicans infection, the 
survival rate data and total flingal load in organs of animals of all groups were 
analyzed. For the assessment of fungal load, two animals from each group were 
sacrificed on day 7* post infection. For each animal, equal tissue of liver, lung, brain 
and spleen was weighed and homogenized in 5 ml. of sterile normal saline and an 
aliquot of this suspension was plated on SD agar plates containing chloramphenicol 
and gentamicin after appropriate dilution, and the plates were incubated for 48-72 
hours at 37 °C. The colonies were counted and the fungal load in different orgaiis was 
calculated by multiplying with the dilution factor. The animals survived on day 40 
post-infection were also screened for fungal load in the same manner. 
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4.3 Results 
4.3.1 Animals immunized with Tuft-lip-Ag show higher antibody titre 
Antibody response was detected in the sera of animals immunized with 
various iiposomised preparations of antigen as well as Ag-IFA combination. Our 
results demonstrate the higher antigen specific antibody titer in the animals 
immunized with antigen containing Tuft-liposomes than those of all other groups 
(Fig. 18). The antigen encapsulated in Egg PC-liposomes was found to be more 
effective in inducing the antibody response in comparison to the Ag-IFA emulsion. 
This result shows the more efficacy of antigen bearing tuft-liposomes in stimulating 
the antibody secreting cells than other combinations of antigen. 
4.3.2 Tuftsin bearing liposomes increase the secretion ratio of IgG2a/IgGl isotype 
The impact of the immunization with the antigen entrapped in the tuftsin 
bearing liposomes was monitored for the generation of antigen reactive IgGl and 
IgG2a isotypes in the sera of the animals inoculated with the antigen entrapped in the 
different types of liposomes. Our results show the significant increase in the secretion 
ratio of IgG2a/ IgGl type of antibodies in the sera of animals immunized with antigen 
entrapped in the Tuft-liposomes (Fig. 19). Besides, the overall production of the 
antibodies was also much higher in the sera of animals immunized with antigen in 
tuftsin bearing liposomes as compared to the animals of the other groups. No antigen 
specific IgGl and IgG2a-isotypes were detected in control groups injected with either 
plain Tuft egg PC/Chol, or plain egg PC/Chol liposomes (no antigen) or PBS. 
4.3.3 Tuftsin-lip-antigen immunized mice have increased survival rates 
The cytosolic fraction of C. neoformans cell extract encapsulated in Tuft-
liposomes prolonged the survival time of the treated animals remarkably when 
compared to animals fi-om other groups in the experiment. Immunization of animals 
with Tuft-lip-antigen provided better protection against C. neoformans infection, and 
percent survival of the animals was found to be 70 % on day 40 post-infection. While 
only 40 % animals survived in the group of animals immunized with PC-lip-Ag and 
Ag-IFA emulsion (Fig. 20). 
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Fig. 19 Antibody isotyping in response to liposomal forms of cytosolic fractions 
of C. neoformans. Results are expressed as mean of responses of five mice in each 
group + S.D. The figure is representative of three different experiments. 
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Fig. 20 Survival of mice immunized with cytosolic proteins entrapped in liposomes 
followed by infection with C. neoformans. Control (•), Tuft-lip (o), IFA-Ag (T) , 
Lip-Ag (A), Tuft-lip-Ag (•). Ten mice were taken in each group and experiment was 
repeated three times. 
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4.3.4 Lip-nystatin in combination of Tuft-Ag immunization shows more antifungal 
efficacy against C. neoformans infection 
Immunization of animals with antigen entrapped in Tuftsin bearing liposomes 
confers higher protection against systemic candidiasis both in terms of survival as 
well as CFU in the lungs and brain. The survival of the animals was further increased 
when liposomal nystatin even at the lower doses (3 mg/kg) was given to the 
immunized animals. The treatment with immunomodulators in combination with 
chemotherapy shows additive effect and therefore found to be more effective in 
reducing the severity of the infection. The Tuftsin-Ag immunized animals treated with 
two doses of liposomal nystatin on the days 1 and 4 after infection have maximum 
survival rate 100 % followed by Lip-Ag immunization plus Lip-nystatin treatment 
(-70 %). On the contrary, the animals treated with only Lip-nystatin (no vaccination) 
have 20 % survival (Fig. 21). 
4.3.5 Fungal burden in lungs and brain 
Severity of the C. neoformans infection in different groups was further 
confirmed by the assessment of the colony forming units (CFU) data in lungs and 
brain of the infected animals. CFU counts determined on day 7 post-infection were 
found least in the animals immunized with Tuft-lip-Ag followed by animals of groups 
vaccinated with PC-lip-Ag and IFA-Ag emulsion respectively (Table 10). 
In the second set of experiment, the animals were treated with liposomal 
nystatin (3 mg/kg) after immunization with different liposomised forms of cytosolic 
antigen of C. neoformans. The CFU load determined in the lungs and brain of the 
animals on day 7 postinfection show increased efficacy of the liposomal nystatin in 
the group of animals immunized with Tuftsin bearing liposomal antigen followed by 
that of PC-Ag and Lip-nystatin combination. Whereas the animals treated with only 
liposomal nystatin show severe infection as reflected by CFU load in their various 
organs (Table 10). 
4.3.6 Tuftsin increases the survival of C. neoformans infected neutropenic mice 
To determine whether immunization of animals using tuftsin liposomes was 
effective in neutropenic condition, mice were made neutropenic by injecting 
cyclophosphamide before each immunization and infection. Infection with 1 x 10^  C 
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Fig. 21 Survival of mice immunized with various adjuvant-antigen combinations 
followed by chemotherapy after infection with C. neoformans. Control (•), Tuft-lip 
(o), Lip-Nys ( • ) , IFA-Ag + lip-Nys (A), Lip-Ag + lip-Nys (•), Tuft-lip-Ag + lip-Nys 
(n). Ten mice were taken in each group and experiment was repeated three times. 
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neoformans cells caused high mortality and all non-immunized mice (Saline group) 
died within 5 days as a result of severe systemic infection in neutropenic animals. 
Animals from saline group died within 5 days of infection. None of the animals 
except those immunized with tuftsin bearing liposomes survived till day 50 of 
observation. Interestingly, neutropenic mice vaccinated with tuftsin liposomal 
formulation of antigen did not allow establishment of infection and -30 % animals 
survived on day 50 (Fig. 22). 
In another set of experiment, the efficacy of chemotherapy was tested in the 
neutropenic mice after immunizing them with various combinations of antigen, 
including tuftsin bearing liposomal antigen. The survival of the neutropenic mice 
immunized with tuft-lip-antigen increases significantly in comparison to other groups 
after treatment with lip-nystatin (Fig. 22). Lip-nystatin at the drug dose (5 mg/kg) 
increases the survival rate upto 60 % while immunized mice without chemotherapy 
have 30 % survival. The unimmunized mice treated with liposomal nystatin show 
only 20 % survival. Surprisingly, there was also 40 % and 30 % survival in the group 
of animals immunized with PC-lip-Ag and IFA-Ag followed by treatment with 
liposomal nystatin. 
4.3.7 Fungal load in lungs and brain of the immunized leukopenic mice 
The role of immunization in controlling C. neoformans infection in leukopenic 
mice was also assessed by culturing lungs and brain homogenates for CPU count. 
Among the various antigen-adjuvant combinations used in the study, antigen 
entrapped in tuftsin bearing liposomes was found to be most effective in imparting 
immunity against C. neoformans infection. When the immunized mice were treated 
with liposomised-nystatin, the effect of chemotherapy was more pronounced in mice 
immunized with Tuft-lip-Ag as evident from cfu data of lungs and brain of treated 
mice (Table 11) 
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Fig. 22 Survival of leukopenic mice immunized with various antigen-adjuvant 
combinations foUovt'ed by chemothnerapy after infection with C. neoformans. 
Saline (•), Tuft-lip (o), Lip-Nys (5 mg/kg) (A), IFA-Ag (V), IFA-Ag (+) lip-Nys (5 
mg/kg) (•), Lip-Ag (+) lip-Nys (5 mg/kg) (D), Tuft-Ag ( • ) , Tuft-Ag (+) lip-Nys (A). 
Ten mice were taken in each group and experiment was repeated three times. 
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IFA-Ag + Lip-Nys vs Tuft-lip-A + Lip-Nys 
Lip-Ag + Lip-Nys vs Tuft-lip-Ag + Lip-Nys 
P value 
0.433 
0.002 
0.015 
Table 10. Role of Lip-Nystatin in combination of immunization against 
establishment of C neoformans infection in mice 
Treatment Group 
Saline 
Tuft-lip 
Lip-Nystatin 
IFA-Antigen 
IFA-Antigen + Lip-Nystatin 
Lip-Antigen 
Lip-Antigen + Lip-Nystatin 
Tuft-lip-Antigen 
Tuft-lip-Ag + Lip-Nystatin 
Fungal load (cfu/ organ) on day 7 
post infection 
Lungs 
116640±34024 
102824± 26286 
48128±10864 
34884± 8222 
16962 ±2612 
30267± 4568 
10428±2160 
11050±1262 
1422±466 
Brain 
92322±22234 
82180±12482 
37084±6224 
28040±4234 
12249± 1610 
20782±5678 
10040±2246 
7828±1324 
626 ±148 
Group 
IFA-Ag vs IFA-Ag + Lip-Nys 
Lip-Ag vs Lip-Ag + Lip-Nys 
Tuft-Ag vs Tuft-Ag + lip-Nys 
IFA-Ag + Lip-Nys vs Tuft-Ag + Lip-Nys 
Lip-Ag + lip-Nys vs Tuft-Ag + Lip-Nys 
P value 
0.024 
<0.001 
<0.001 
<0.001 
<0.001 
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Table 11. Role of Lip-Nystatin in combination of immunization against 
establishment of C. neoformans infection in leukopenic mice 
Treatment Group 
Saline 
Tuft-lip 
Lip-Nystatin 
IFA-Antigen 
IFA-Antigen + Lip-Nystatin 
Lip-Antigen 
Lip-Antigen + Lip-Nystatin 
Tuft-lip-Antigen 
Tuft-lip-Ag + Lip-Nystatin 
Fungal load (cfu/gm. of organ) 
on day 5 post infection 
Lungs 
194048±32248 
182445± 36624 
88128± 11644 
128842± 18128 
49620 ±6928 
102673±14582 
44285±8608 
71504±9162 
24224±6460 
Brain 
129302±23342 
118024±14822 
57084±6646 
80404±9340 
32292±6104 
78246±10678 
22040±8466 
47182±5248 
16262±1848 
Group 
IFA-Ag vs IFA-Ag + Lip-Nys 
Lip-Ag vs Lip-Ag + Lip-Nys 
Tuft-Ag vs Tuft-Ag + Lip-Nys 
IFA-Ag + Lip-Nys vs Tuft-Ag + Lip-|^ lys 
Lip-Ag + Lip-Nys vs Tuft-Ag + Lip-Nys 
P value 
<0.002 
<0.003 
<0.001 
<0.010 
0.036 
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Discussion 
4.4 Discussion 
Cryptococcus neoformans is an encapsulated fungus that forms a significant 
cause of morbidity and mortality in patients with impaired cell-mediated immunity, 
especially those with AIDS background (Chuck and Sande, 1989). It seems 
polysaccharide moieties of C. neoformans capsule wall enhance HIV replication 
(Pettoello-Mantovani et al, 1992). The infection often relapses in persons with 
impaired immunity even when supplemented with antifungal chemotherapy. 
The difficulties associated in the management of cryptococcal infections in patients 
with AIDS have instilled a great deal of interest in the potential of antibody immunity 
for prevention and adjunctive therapy (Yuan et al, 1997). For management of 
Cryptococcosis, the use immunomodulatory components as a part of immunotherapy 
are of utmost importance. The use of immunostimulating agents as carrier of vaccine 
may be proved effective in elimination of C. neoformans infection including other 
opportunistic infections. The present study documents the development of potential 
vaccine formulation that induces protective responses against systemic C. neoformans 
infection in mice. Mice immunized with antigen encapsulated in Tuftsin bearing 
liposomes have prolonged survival time in comparison to mice vaccinated with Lip-
Ag or IFA-Ag. 
In the present investigation, we have demonstrated the effectiveness of 
liposome-based vaccine against C. neoformans infection in neutropenic mice as well. 
For immunization of animals, various liposomised formulations of cytosolic proteins 
of animals were administered in different groups of neutropenic animals. C. 
neoformans cytosolic antigen were given as liposomal preparations including the one 
incorporated with immunomodulator tuftsin. Mice immunized with Tuft-lip-Ag show 
high titer of antibodies in their sera. It has already been shown that tuftsin when 
covalently linked to BSA augments antibody production, whereas BSA alone or 
physical mixture of BSA administered with tuftsin has no such immunogenic effect 
(Dagan et al, 1987). Tuftsin does potentiate the immunogenic capacity of the 
macrophages transforming some weak immunogens to potent immunogens (Dagan et 
al, 1987). Tuftsin also augments the production of IL-1 in presence of antigen (Dagan 
et al, 1988). 
90 
The antibody isotyping results also favor the role of tuftsin in protection of 
mice against C. neoformans infection. The animals immunized with Tuft-lip-Ag show 
the substantial amount of IgG2a isotype, which suggests the Thl/Th2 polarization in 
favor of Thl. This shows that immunization using tuftsin liposomes induces the 
development of protective antifungal Thl response. This is ftirther supported by the 
results of survival of mice and clearance of C. neoformans from the host tissues. 
Polytuftsin in conjugation with malaria peptide selectively enhances MHC 
class II molecules on antigen presenting cells and may, therefore, stimulate better 
antigen presentation and proliferation of T cells (Dhawan et al, 1995). Tuftsin upon 
incorporation in liposomes enhances the antigen specific T cell proliferation 
remarkably against other model antigen such as ovalbumin as compared to OVA 
injected with IF A or in liposomes without tuftsin. It seems that T cells along with 
specific antibodies successfiiUy eliminate C. neoformans infection fi-om the host 
(Yuan e/a/, 1997). 
The prophylactic role of tuftsin in imparting protection against C neoformans 
infection was also supported by survival data of the treated animals. Animals 
immunized with tuftsin bearing liposomal antigen showed high survival rate (70 %) 
while the group that was immunized with Lip-Ag or IFA-Ag showed only 40 % 
survival of total animals (Fig. 20). The increased survival in the group vaccinated 
with antigen bearing tuftsin liposomes can be attributed to the tuftsin-mediated 
activation of the antigen presenting cells (cf macrophages), which results in induction 
of both humoral as well as cell mediated branches of the immune system. 
Polymorphonuclear cells (PMN) including neutrophils can exert antimicrobial 
activity by two general mechanisms, oxidative and nonoxidative. The former is 
characterized by the respiratory burst, a process whereby molecular oxygen is 
consumed and reduced to superoxide anion (Robinson and Badwey, 1994). Tuftsin 
mediated stimulation of macrophages and neutrophils results in the generation of 
reactive oxygen and nitrogen intermediaries with potent antimicrobial activity. 
Several studies have demonstrated that oxidative mechanisms contribute in 
elimination of C. neoformans infection (Chaturvedi et al, 1996). In fact these 
oxidants have been shown to kill C. neoformans in cell free system (Chaturvedi et al, 
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1996). Besides, the presence of antibodies has been found to potentiate 
anticryptococcal effect of leukocytes (Miller and Kohl, 1983). The role of these front 
line defence cells have been found very crucial for protecting the host from 
opportunistic pathogens. The depletion of leukocytes from the model animals makes 
them highly susceptible to C neoformans and leukopenic animals upon immunization 
show very low level of antibody titer. The severity of the infection in leukopenic 
animals was very high as evident from enormous numbers of colony forming units in 
the lungs and spleen of the infected animals. 
The increased survival and comparatively low level of fungal burden in 
leukopenic mice immunized with antigen bearing tuftsin liposomes support the idea 
of using these liposomes for vaccination against C. neoformans infection in 
immunocompromised persons who poorly respond to chemotherapy. 
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